Schedule 1—Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

Note: See sections 5 and 6.

Permissible ingredients and requirements

Column 1

Column 2

Column 3

Column 4

Item

Ingredient name

Purpose

Specific requirements

3647

P-ALPHA-DIMETHYL STYRENE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3648

P-ANISIC ACID

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.3%.

 

3649

PADIMATE O

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 8%.

When used in primary sunscreen products, the following warning statements are required on the label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

3650

PADINA PAVONICA THALLUS PHYTOSTEROLS

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.01%.

 

3651

PAEONIA LACTIFLORA

A, E, H

 

3652

PAEONIA OBOVATA

A, H

 

3653

PAEONIA SUFFRUTICOSA

A, E, H

 

3654

PAEONIA VEITCHII

A, H

 

3655

PALIURUS SPINA-CHRISTI

A, H

 

3656

PALLADIUM

H

Only for use as an active homoeopathic ingredient.

 

3657

PALM FRUIT OIL

A, E, H

 

3658

PALM GLYCERIDES

E

 

3659

PALM KERNEL OIL

A, E, H

 

3660

PALM TOCOTRIENOLS COMPLEX

A, H

 

3661

PALMARIA PALMATA

A, H

 

3662

PALMAROSA OIL

A, E, H

 

3663

PALMIDROL

A

Only permitted for use in medicines limited to oral routes of administration.

The maximum recommended daily dose of the medicine must not provide more than 600 mg of palmidrol.

The following warning statements (or words to the same effect) are required on the medicine label:

- (ANALG) 'The medicine may interact with other prescription analgesic medicines, please consult your healthcare practitioner before use.'

- (ADULT) ‘Adults only.’

- (21DAYS) ‘Not to be used for more than 21 consecutive days.’

 

3664

PALMITIC ACID

E

 

3665

PALMITOLEIC ACID-RICH FATTY ACID ETHYL ESTERS

A

 

3666

PALMITOYL DIPEPTIDE-7

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.002%.

 

3667

PALMITOYL HYDROXYPROPYLTRIMONIUM AMYLOPECTIN/GLYCERIN CROSSPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.01%

 

3668

PALMITOYL OLIGOPEPTIDE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.002%.

 

3669

PALMITOYL PENTAPEPTIDE-3

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.0005%.

 

3670

PALMITOYL TETRAPEPTIDE-3

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.001%.

 

3671

PANAX GINSENG

A, E, H

 

3672

PANAX JAPONICUS

A, H

 

3673

PANAX NOTOGINSENG

A, H

 

3674

PANAX PSEUDOGINSENG

A, H

 

3675

PANAX QUINQUEFOLIUS

A, H

 

3676

PANICUM MILIACEUM

A, H

 

3677

PANTETHINE

E

Only for use in topical medicines for dermal application.

 

3678

PANTHENOL

A, E

 

3679

PANTHENYL ETHYL ETHER

E

Only for use in topical medicines for dermal application.

 

3680

PANTOLACTONE

E

 

3681

PANTOTHENIC ACID

A, E

When used topically, the concentration in the medicine must be no more than 0.1%.

 

3682

PANTOTHENIC ACID POLYPEPTIDE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

3683

PAPAIN

A, E

 

3684

PAPER

E

Only for use in topical medicines for dermal application.

 

3685

PAPRIKA OLEORESIN

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3686

PARA-CRESOL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3687

PARA-CRESYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3688

PARA-CRESYL ISOBUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3689

PARA-CRESYL PHENYLACETATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3690

PARA-CYMENE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3691

PARA-ETHOXYBENZALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3692

PARA-ETHYL CRESOXYACETATE

E

Para-ethyl cresoxyacetate must only be included in medicines when in combination with other permitted ingredients as a fragrance proprietary excipient formulation.

The total concentration of the fragrance proprietary excipient formulation containing para-ethyl cresoxyacetate must not be more than 1% of the total medicine.

 

3693

PARA-ETHYLPHENOL

E

Permitted for use only in combination with other permitted ingredients as part of a flavour proprietary excipient formulation.

The maximum recommended daily dose must contain no more than 0.12 mg of para-ethylphenol.

The total flavour proprietary excipient formulation in a medicine must be no more than 5%.

 

3694

PARA-HYDROXY BENZALACETONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3695

PARA-HYDROXYBENZOIC ACID

E

 

3696

PARA-MENTHA-8-THIOL-3-ONE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3697

PARA-METHYL ACETOPHENONE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3698

PARA-METHYL ANISOLE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3699

PARA-METHYL DIMETHYLBENZYL CARBINOL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3700

PARA-PROPYL ANISOLE

E

Para-propyl anisole must only be included in medicines when in combination with other permitted ingredients as a fragrance and/or flavour proprietary excipient formulation.

 The total concentration of fragrance proprietary excipient formulations containing para-propyl anisole must not be more than 1% of the total medicine.

The total concentration of flavour proprietary excipient formulations containing para-propyl anisole must not be more than 5% of the total medicine.

 

3701

PARA-TERT-BUTYLCYCLOHEXYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3702

PARA-TERT-BUTYLPHENYL-ALPHA-METHYLHYDROCINNAMIC ALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3703

PARA-TOLUALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3704

PARA-TOLYL ACETALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3705

PARAMERIA LAEVIGATA

A, H

 

3706

PARIETARIA JUDAICA

A, H

 

3707

PARIS POLYPHYLLA

A, H

 

3708

PARIS QUADRIFOLIA

A, H

 

3709

PARSLEY

E, H

 

3710

PARSLEY HERB DRY

A, E, H

 

3711

PARSLEY HERB OIL

A, E, H

 

3712

PARSLEY HERB POWDER

A, E, H

 

3713

PARSLEY SEED OIL

A, E, H

 

3714

PARTHENOCISSUS TRICUSPIDATA

A, H

 

3715

PARTIALLY DEHYDRATED LIQUID SORBITOL

E

Sorbitol is a mandatory component of partially dehydrated liquid sorbitol.

Permitted for use only as part of the capsule in medicines where the dosage form is a soft capsule.

 

3716

PARTIALLY HYDROGENATED SOYA OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in the medicine must be no more than 5%.

 

3717

PARTIALLY REFINED PORPHYRA YEZOENSIS CYTOPLASM EXTRACT

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.00002%.

 

3718

PASPALUM NOTATUM

A, H

 

3719

PASSIFLORA CAERULEA

A, H

 

3720

PASSIFLORA EDULIS

E

 

3721

PASSIFLORA HERB DRY

A, H

 

3722

PASSIFLORA INCARNATA

A, E, H

 

3723

PATCHOULI OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3724

PATENT BLUE V

E

Permitted for use only as a colour in medicines limited to topical and oral routes of administration.

 

3725

PATENT BLUE V ALUMINIUM LAKE

E

Permitted for use only as a colour in medicines limited to topical and oral routes of administration.

 

3726

PATRINIA SCABIOSIFOLIA

A, H

 

3727

PATRINIA VILLOSA

A, H

 

3728

PAULLINIA CUPANA

A, E, H

Caffeine is a mandatory component of Paullinia cupana.

When the medicine is packaged for supply as a divided preparation and is for internal use or oral application, the medicine must not contain a concentration of total caffeine greater than 33%.

When for internal use or oral application, the maximum recommended daily dose of the medicine must provide no more than 400 mg of total caffeine.

When the medicine is packaged for supply as an undivided preparation and is for internal use or oral application, the medicine must not contain a concentration of total caffeine greater than 1%.

When the medicine is for internal use or oral application, a maximum recommended dose of the medicine must not provide more than 100 mg of total caffeine within a 3 hour period.

When the maximum recommended daily dose of the medicine provides greater than 10 mg of total caffeine and the medicine is for internal use or oral application, the following warning statements are required on the label:

- (ADULT) 'Adults only' (or words to that effect).

- (CAFF) 'Contains [state quantity per dosage unit or per mL or per gram of product] total caffeine [per dosage unit or per mL or per gram]. A cup of instant coffee contains approximately 80mg of caffeine.'

- (CAFFPREG) ‘Caffeine intake more than 200 mg per day is not recommended during pregnancy or breastfeeding.’

When the maximum recommended daily dose of the medicine provides greater than 80 mg of total caffeine and the medicines is for internal use or oral application, the following warning statements are required on the label:

- (CAFFLMT) 'Limit the use of caffeine-containing products (including tea and coffee) when taking this product.'

- (CAFFCYP) ‘Caffeine interacts with enzyme CYP1A2 in the liver. Consult your health professional before taking with other medicines’ (or words to that effect).

 

3729

PAULLINIA PINNATA

A, H

 

3730

PAWPAW

E

 

3731

PEA

E

 

3732

PEA STARCH

E

 

3733

PEACH

E

 

3734

PEANUT

E

 

3735

PEAR

E

 

3736

PECAN

E

 

3737

PECTIN

A, E

 

3738

PEG-10 DIMETICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or damaged skin.

The concentration in the medicine must be no more than 4.0%.

 

3739

PEG-10 SOYA STEROL

E

Only for use in topical medicines for dermal application.

 

3740

PEG-100 STEARATE

E

Only for use in topical medicines for dermal application.

 

3741

PEG-12 DILAURATE

E

 

3742

PEG-12 DIMETICONE/PPG-20 CROSSPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 2%.

 

3743

PEG-120 METHYL GLUCOSE DIOLEATE

E

Only for use in topical medicines for dermal application.

 

3744

PEG-120 STEARATE

E

Only for use in topical medicines for dermal application.

 

3745

PEG-15 COCAMINE

E

Only for use in topical medicines for dermal application.

 

3746

PEG-150 DISTEARATE

E

Only for use in topical medicines for dermal application.

 

3747

PEG-20 ALMOND GLYCERIDES

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

3748

PEG-20 METHYL GLUCOSE DISTEARATE

E

Only for use in topical medicines for dermal application.

 

3749

PEG-20 METHYL GLUCOSE SESQUISTEARATE

E

Only for use in topical medicines for dermal application.

 

3750

PEG-20 SORBITAN ISOSTEARATE

E

Only for use in topical medicines for dermal application.

 

3751

PEG-20 STEARATE

E

Only for use in topical medicines for dermal application.

 

3752

PEG-25 PABA

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 10%.

When used in primary sunscreen products, the following warning statements are required on the label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

3753

PEG-30 DIPOLYHYDROXYSTEARATE

E

Only for use in topical medicines for dermal application.

 

3754

PEG-30 STEARATE

E

Only for use in topical medicines for dermal application.

 

3755

PEG-35 CASTOR OIL

E

 

3756

PEG-4 DILAURATE

E

Only for use in topical medicines for dermal application.

 

3757

PEG-4 LAURATE

E

Only for use in topical medicines for dermal application.

Dioxane and Ethylene oxide are mandatory components of PEG-4 laurate.

The concentration of Dioxane in the medicine must be no more than 10 mg/kg or 10 mg/L or 0.001%.

The concentration of Ethylene oxide in the medicine must be no more than 1 mg/kg or 1 mg/L or 0.0001%.

 

3758

PEG-4 STEARATE

E

Only for use in topical medicines for dermal application.

 

3759

PEG-40 CASTOR OIL

E

 

3760

PEG-40 HYDROGENATED CASTOR OIL

E

 

3761

PEG-40 SORBITAN DIISOSTEARATE

E

Only for use in topical medicines for dermal application.

Dioxane and Ethylene oxide are mandatory components of PEG-40 sorbitan diisostearate.

The concentration of Dioxane in the medicine must be no more than 10 mg/kg or 10 mg/L or 0.001%.

The concentration of Ethylene oxide in the medicine must be no more than 1 mg/kg or 1 mg/L or 0.0001%.

 

3762

PEG-40 STEARATE

E

Only for use in topical medicines for dermal application.

 

3763

PEG-45/DODECYL GLYCOL COPOLYMER

E

Only for use in topical medicines for dermal application.

 

3764

PEG-5 GLYCERYL STEARATE

E

Only for use in topical medicines for dermal application.

 

3765

PEG-50 STEARATE

E

Only for use in topical medicines for dermal application.

 

3766

PEG-55 PROPYLENE GLYCOL OLEATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.6%.

 

3767

PEG-6 LAURAMIDE

E

Only for use in topical medicines for dermal application.

 

3768

PEG-60 ALMOND GLYCERIDES

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration when used in medicines applied directly to the skin must be no more than 10%.

The concentration when used in bath oil medicines must be no more than 30%.

 

3769

PEG-60 GLYCERYL ISOSTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2%.

 

3770

PEG-60 HYDROGENATED CASTOR OIL

E

Only for use in topical medicines for dermal application.

 

3771

PEG-7 COCAMIDE

E

Only for use in topical medicines for dermal application.

 

3772

PEG-7 GLYCERYL COCOATE

E

Only for use in topical medicines for dermal application.

 

3773

PEG-7 HYDROGENATED CASTOR OIL

E

Only for use in topical medicines for dermal application.

 

3774

PEG-75 LANOLIN

E

Only for use in topical medicines for dermal application.

 

3775

PEG-75 STEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1.5%.

 

3776

PEG-8 CETYL DIMETHICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.0005%.

 

3777

PEG-8 DILAURATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4%.

 

3778

PEG-8 DISTEARATE

E

Only for use in topical medicines for dermal application.

 

3779

PEG-8 LAURATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4%.

The levels of possible impurities such as ethylene oxide (and related material) must be kept below the level of detection.

 

3780

PEG-8 PROPYLENE GLYCOL COCOATE

E

 

3781

PEG-8 STEARATE

E

Only for use in topical medicines for dermal application.

 

3782

PEG-9 POLYDIMETHYLSILOXYETHYL DIMETICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 3.5%.

 

3783

PEG/PPG-14/7 DIMETHYL ETHER

E

Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 7%.

 

3784

PEG/PPG-18/18 DIMETHICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

3785

PELARGONIUM GRAVEOLENS

A, E, H

 

3786

PELLITORINE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3787

PELTIGERA CANINA

A, H

 

3788

PENICILLIUM EXPANSUM

A, H

 

3789

PENNYROYAL OIL

E

D-Pulegone/Pulegone is a mandatory component of Pennyroyal Oil.

The concentration of D Pulegone/ Pulegone in the medicine must be no more than 4%.

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in the medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in the medicine must be no more than 1%.

When the medicine is for a use other than topical, the maximum recommended daily dose must be no more than 50 mg of Pennyroyal Oil.

 

3790

PENTAERYTHRITYL TETRA-DI-T-BUTYL HYDROXYHYDROCINNAMATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.018%

 

3791

PENTAERYTHRITYL TETRAISOSTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 61%.

 

3792

PENTAERYTHRITYL TETRALAURATE

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 80%.

 

3793

PENTAMETHYLHEPTENONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3794

PENTANE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3795

PENTASODIUM ETHYLENEDIAMINE TETRAMETHYLENE PHOSPHONATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

3796

PENTYLENE GLYCOL

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

3797

PEPPER BLACK

E, H

 

3798

PEPPER OIL TERPENELESS

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3799

PEPPER WHITE

E, H

 

3800

PEPPERMINT AMERICAN EXT.

E

Menthol is a mandatory component of peppermint american ext.

When the medicine is for topical use for dermal application:

a) the medicine must not be intended for use in the eye or on damaged skin;

b) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;

c) the following warning statement is required on the medicine label:

- (EYE) Avoid contact with eyes (or words to that effect).

d) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use.

e) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label:

– (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.

When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

3801

PEPPERMINT LEAF DRY

A, E, H

Menthol is a mandatory component of peppermint leaf dry.

When the medicine is for topical use for dermal application:

(i) the medicine must not be intended for use in the eye or on damaged skin;

(ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;

(iii) the following warning statement is required on the medicine label:

- (EYE) Avoid contact with eyes (or words to that effect).

(iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use.

(v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label:

– (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.

When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

3802

PEPPERMINT LEAF POWDER

A, E, H

Menthol is a mandatory component of peppermint leaf powder.

When the medicine is for topical use for dermal application:

(i) the medicine must not be intended for use in the eye or on damaged skin;

(ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;

(iii) the following warning statement is required on the medicine label:

- (EYE) Avoid contact with eyes (or words to that effect).

(iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use.

(v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label:

– (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.

When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

3803

PEPPERMINT OIL

A, E, H

Menthol is a mandatory component of peppermint oil.

When the medicine is for topical use for dermal application:

(i) the medicine must not be intended for use in the eye or on damaged skin;

(ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;

(iii) the following warning statement is required on the medicine label:

- (EYE) Avoid contact with eyes (or words to that effect).

(iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use.

(v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label:

– (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.

When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

3804

PEPPERMINT OIL TERPENELESS

E

Permitted for use only in combination with other permitted ingredients as a flavour proprietary excipient formulation or fragrance proprietary excipient formulation.

The total flavour proprietary excipient formulation in a medicine must be no more than 5%.

The total fragrance proprietary excipient formulation in a medicine must be no more 1%.

Menthol is a mandatory component of peppermint oil terpeneless.

When the medicine is for topical use for dermal application:

i) the medicine must not be intended for use in the eye or on damaged skin;

ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;

iii) the following warning statement is required on the medicine label:

- (EYE) Avoid contact with eyes (or words to that effect).

iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use.

v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label:

– (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.

When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

3805

PEPPERMINT OIL TERPENES AND TERPENOIDS

E

Permitted for use only in combination with other permitted ingredients as a flavour proprietary excipient formulation.

The total flavour proprietary excipient formulation in a medicine must be no more than 5%.

Menthol is a mandatory component of peppermint oil terpenes and terpenoids.

When the medicine is for topical use for dermal application:

i) the medicine must not be intended for use in the eye or on damaged skin;

ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;

iii) the following warning statement is required on the medicine label:

- (EYE) Avoid contact with eyes (or words to that effect).

iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use.

v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label:

– (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.

When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

3806

PERFLUOROPOLYMETHYLISOPROPYL ETHER

E

Only for use in topical medicines for dermal application.

 

3807

PERHYDRO-3,6-DIMETHYL-BENZO [B] FURAN-2-ONE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3808

PERILLA FRUTESCENS

A, E, H

 

3809

PERILLALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3810

PERLITE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2%.

 

3811

PERMETHRIN

E

The total concentration of permethrin in the medicine must not be more than 2%.

 

3812

PERSEA AMERICANA

A, E, H

 

3813

PERSIC OIL

A, E, H

Amygdalin and Hydrocyanic acid are mandatory components of Persic oil.

The concentration of amygdalin in the medicine must be no more than 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

3814

PERSICARIA CHINENSIS

A, H

 

3815

PERSICARIA TINCTORIA

A, H

 

3816

PERSIMMON

E

 

3817

PERU BALSAM

A, E, H

 

3818

PERU BALSAM OIL

A, E, H

 

3819

PETITGRAIN MANDARIN OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour

The final concentration of the oil in the flavour does not exceed 30%

If used in a flavour the total flavour concentration in a medicine must be no more than 5%

 

3820

PETITGRAIN OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3821

PETITGRAIN OIL CITRONNIER

E

Permitted for use only in combination with other permitted ingredients as part of a fragrance proprietary excipient formulation.

When included in a medicine for use on the lips the concentration of petitgrain oil citronnier must be no more than 0.1%.

When included in dermal creams for infant use the concentration of petitgrain oil citronnier must be no more than 0.5%

The total fragrance proprietary excipient formulation in a medicine must be no more than 1%.

 

3822

PETITGRAIN OIL PARAGUAY

A, E, H

When used internally, oxedrine is a mandatory component of petitgrain oil paraguay.

The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams.

 

3823

PETITGRAIN OIL TERPENELESS

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3824

PETROSELINUM CRISPUM

A, E, H

 

3825

PEUCEDANUM PRAERUPTORUM

A, E, H

 

3826

PEUMUS BOLDUS

A, H

Volatile oil components (of Peumus boldus) is a mandatory component.

The maximum recommended daily dose must be no more than 100 mg of volatile oil components (of Peumus boldus).

 

3827

PHALARIS ARUNDINACEA

A, H

 

3828

PHALARIS CANARIENSIS

A, H

 

3829

PHASEOLUS COCCINEUS

A, H

 

3830

PHASEOLUS VULGARIS

A, H

 

3831

PHELLINUS ROBINIAE

A, E, H

 

3832

PHELLODENDRON AMURENSE

A, E, H

 

3833

PHELLODENDRON CHINENSE

A, H

 

3834

PHENACETIN

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 0.1%.

 

3835

PHENETHYL 2-METHYLBUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3836

PHENETHYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3837

PHENETHYL ALCOHOL

E

Permitted for use only:

a) in topical medicines for dermal application; and

b) for internal use in combination with other permitted ingredients as part of a flavour proprietary excipient formulation.

The total flavour proprietary excipient formulation concentration in a medicine must be no more than 5%.

 

3838

PHENETHYL BENZOATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 6%.

 

3839

PHENETHYL DIMETHICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.2%

 

3840

PHENETHYL ISOAMYL ETHER

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used as in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3841

PHENETHYL ISOBUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3842

PHENETHYL ISOVALERATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3843

PHENETHYL PHENYLACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3844

PHENETHYL SALICYLATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3845

PHENOL

E

Only for use in topical medicines for dermal application.

The concentration of phenol in the medicine must be no more than 1%.

 

3846

PHENOXYACETALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3847

PHENOXYETHANOL

E

Only for use in topical medicines for dermal application.

The concentration of phenoxyethanol in the preparation must not exceed 15%.

 

3848

PHENOXYETHYL ISOBUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3849

PHENOXYETHYLPARABEN

E

Only for use in topical medicines for dermal application.

 

3850

PHENYL DIMETHICONE

E

Only for use in topical medicines for dermal application.

 

3851

PHENYL TRIMETHICONE

E

Only for use in topical medicines for dermal application.

 

3852

PHENYLACETALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3853

PHENYLACETALDEHYDE DIMETHYL ACETAL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3854

PHENYLACETALDEHYDE GLYCERYLACETAL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3855

PHENYLACETIC ACID

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3856

PHENYLALANINE

A, E

When the maximum recommended daily dose of the medicine provides more than 500 mg phenylalanine, the following warning statement is required on the medicine label:

- (PREGNT2) 'Do not use if pregnant or likely to become pregnant'.

 

3857

PHENYLBENZIMIDAZOLE SULFONIC ACID

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 4%.

When used in primary sunscreen products, the following warning statements are required on the label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

3858

PHENYLETHYL BUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3859

PHENYLETHYL CAPROATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3860

PHENYLETHYL CAPRYLATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3861

PHENYLETHYL CINNAMATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3862

PHENYLETHYL FORMATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3863

PHENYLETHYL METHYLETHYL CARBINOL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3864

PHENYLETHYL PROPIONATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3865

PHENYLETHYL TIGLATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3866

PHENYLISOPROPYL DIMETICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

3867

PHENYLPROPANOL

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.16%.

 

3868

PHLEUM PRATENSE

A, H

 

3869

PHLOXINE B

E

Permitted for use only as a colour in medicines limited to topical and oral routes of administration.

 

3870

PHLOXINE B ALUMINIUM LAKE

E

Permitted for use only as a colour in medicines limited to topical and oral routes of administration.

 

3871

PHOENIX DACTYLIFERA

A, E, H

 

3872

PHOSPHATIDYL CHOLINE

E

 

3873

PHOSPHOLIPIDS

E

Only for use in topical medicines for dermal application and not intended for use in the eye.

The concentration in the medicine must be no more than 20%.

 

3874

PHOSPHORIC ACID

E, H

The concentration in liquid medicines must be no more than 15%.

 

3875

PHOSPHORUS

H

Only for use as an active homoeopathic ingredient.

The total concentration of phosphorus in the medicine must not be more than 1 mg/kg or 1 mg/L or 0.0001%.

 

3876

PHOTINIA SERRULATA

A, H

 

3877

PHRAGMITES AUSTRALIS

A, H

 

3878

PHYLLANTHUS AMARUS

A, H

 

3879

PHYLLANTHUS EMBLICA

A, E, H

When used as an excipient, only for use in topical medicines for dermal application.

 

3880

PHYLLOSTACHYS NIGRA

A, E, H

 

3881

PHYSALIS ALKEKENGI

A, H

 

3882

PHYSALIS PUBESCENS

A, H

 

3883

PHYTANTRIOL

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 0.5%.

 

3884

PHYTOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3885

PHYTOLACCA AMERICANA

A, H

The maximum recommended daily dose of the medicine must contain no more than 1mg of the equivalent dry herb.

 

3886

PHYTOMENADIONE

A, E

 

3887

PHYTOSPHINGOSINE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

3888

PHYTOSTERYL/OCTYLDODECYL LAUROYL GLUTAMATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

3889

PICEA ABIES

A, H

 

3890

PICEA MARIANA

A, H

 

3891

PICRASMA EXCELSA

A, E, H

 

3892

PICRORRHIZA KURROA

A, E, H

 

3893

PIGMENT BLUE 15

E

Permitted for use only as a colour for topical and dental use.

The concentration in medicine must be no more than 0.003%.

 

3894

PIGMENT BLUE 15:1

E

Permitted for use only as a colour for topical use.

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.21%.

 

3895

PIGMENT GREEN 7

E

Permitted for use only as a colour for topical and dental use.

When for dental use, the concentration in the medicine must be no more than 0.003%.

When for topical use, the concentration in the medicine must be no more than 0.17%.

 

3896

PIGMENT RED 4

E

Permitted for use only as a colour for topical use.

 

3897

PIGMENT RED 53

E

Permitted for use only as a colour for topical use.

 

3898

PIGMENT RED 57

E

Permitted for use only as a colour for topical use.

 

3899

PIGMENT RED 57 ALUMINIUM LAKE

E

Permitted for use only as a colour for topical use.

 

3900

PIGMENT RED 57 BARIUM LAKE

E

Permitted for excipient use as a colour in topical medicines for dermal application.

Not to be included in medicines intended for use in the eye.

 

3901

PIGMENT RED 63

E

Permitted for use only as a colour for topical use.

 

3902

PIGMENT WHITE 26

E

Permitted for use only as a colour for topical use.

 

3903

PIGMENT YELLOW 12

E

Permitted for use only as a colour for topical use.

 

3904

PILOCARPUS JABORANDI

A, H

Pilocarpine is a mandatory component of Pilocarpus  jaborandi.

The concentration of pilocarpine in the medicine must be no more than 0.025%.

 

3905

PILOCARPUS MICROPHYLLUS

A, H

Pilocarpine is a mandatory component of Pilocarpus microphyllus.

The concentration of pilocarpine in the medicine must be no more than 0.025%.

 

3906

PILOCARPUS PINNATIFOLIUS

A, H

Pilocarpine is a mandatory component of Pilocarpus pinnatifolius.

The concentration of pilocarpine in the medicine must be no more than 0.025%.

 

3907

PIMENTA FRUIT OIL

A, E, H

 

3908

PIMENTA LEAF OIL

A, E, H

 

3909

PIMENTA OFFICINALIS

A, E, H

 

3910

PIMENTA RACEMOSA

A, E, H

When the plant preparation for Pimenta racemosa is an oil and the concentration of this oil in the medicine is more than 25%, the nominal capacity of the container must be no more than 25 mL.

When the plant preparation for Pimenta racemosa is an oil, the concentration of this oil in the medicine is more than 25%, and  the nominal capacity of the container is more than 15 mL, a restricted flow insert must be fitted on the container.

When the plant preparation for Pimenta racemosa is an oil, the concentration of this oil in the medicine is more than 25%, and the nominal capacity of the container is more than 15 mL but no more than 25 mL, a child resistant closure and restricted flow insert must be fitted on the container.

The medicine requires the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or word to that effect)

- (NTAKEN) 'Not to be taken'.

 

3911

PIMPINELLA ANISUM

A, E, H

When the plant preparation for Pimpinella anisum is an oil or distillate and the concentration of this oil or distillate in the medicine is more than 50%:

a) the nominal capacity of the container must be no more than 50 millilitres; and

b) a restricted flow insert is must be fitted on the container; and

c) the medicine requires the following warning statement on the medicine label:

- (CHILD) ‘Keep out of reach of children’ (or words to that effect).

 

3912

PIMPINELLA SAXIFRAGA

A, E, H

 

3913

PINE NEEDLE OIL SCOTCH

A, E, H

 

3914

PINE NEEDLE OIL TERPENELESS

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3915

PINE OIL AROMATIC

A, E, H

 

3916

PINE OIL PUMILIO

A, E, H

 

3917

PINEAPPLE

E

 

3918

PINEAPPLE OILS

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3919

PINELLIA TERNATA

A, H

 

3920

PINUS CONTORTA

A, E, H

 

3921

PINUS ELLIOTTII

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3922

PINUS MASSONIANA

A, E, H

When the plant preparation is oil or distillate the total concentration of Pinus massoniana oil or distillate in the preparation must be no more than 25%.

 

3923

PINUS MONTICOLA

A, E, H

 

3924

PINUS MUGO

A, E, H

 

3925

PINUS PALUSTRIS

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3926

PINUS PINASTER

A, E, H

When the plant preparation is oil or distillate the total concentration of Pinus pinaster oil or distillate in the preparation must be no more than 25%.

 

3927

PINUS PONDEROSA

A, E, H

 

3928

PINUS RADIATA

A, E, H

 

3929

PINUS STROBUS

A, E, H

 

3930

PINUS SYLVESTRIS

A, E, H

 

3931

PINUS TABULIFORMIS

A, E, H

 

3932

PINUS YUNNANENSIS

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3933

PIPENZOLATE BROMIDE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3934

PIPER CHABA

A, E, H

 

3935

PIPER CUBEBA

A, E, H

 

3936

PIPER KADSURA

A, E, H

 

3937

PIPER LONGUM

A, E, H

 

3938

PIPER METHYSTICUM

A, H

Kavalactones (of Piper methysticum) is a mandatory component of Piper methysticum.

Only for oral use when the dosage form is 'tablet' or 'capsule'; or when the container type is 'tea bag'.

When used in oral medicines, the maximum daily dose of kavalactones (of Piper methysticum) must be no more than 250 mg.

If the dosage form is tablet or capsule then the quantity of kavalactones (of Piper methysticum) must be no more than 125 mg per tablet or capsule.

Oral medicines containing more than 25 mg of kavalactones (of Piper methysticum) per dose require the following warning statement on the medicine label:

- (PIPER) 'Not for prolonged use. If symptoms persist - seek advice from a healthcare practitioner. Not recommended for pregnant or lactating women (or words to that effect). May harm the liver'.

The plant part must be root or rhizome.

When for oral use, the medicine may only contain dried whole or peeled root or rhizome or aqueous dispersions or aqueous extracts of whole or peeled root or rhizome.

When for topical use on the rectum, vagina or throat, the medicine may only contain dried whole or peeled root or rhizome or aqueous dispersions or aqueous extracts of whole or peeled root or rhizome.

When the container type is tea bag the maximum quantity per tea bag must be no more than 3 grams of dried whole or peeled root or rhizomes.

 

3939

PIPER NIGRUM

A, E, H

 

3940

PIPER SARMENTOSUM

A, E, H

 

3941

PIPERINE

E

Permitted for use only in combination with other permitted ingredients as a flavour proprietary formulation.

The total flavour proprietary formulation in a medicine must not be more than 5% and the concentration of piperine in the medicine must not be more than 0.15%.

 

3942

PIPERITONE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3943

PIPERONAL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3944

PIPERONYL ACETONE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used as a flavour the total flavour concentration in a medicine must be no more than 5%.

If used as in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3945

PIPERONYL BUTOXIDE

E

Only for use in topical medicines for dermal application.

 

3946

PIROCTONE OLAMINE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1% in wash-on/wash-off medicines and 0.5% in leave-on medicines.

 

3947

PISCIDIA PISCIPULA

A, E, H

 

3948

PISTACIA LENTISCUS

A, E, H

 

3949

PISUM SATIVUM

A, E, H

 

3950

PLACENTA

H

Only for use as an active homoeopathic ingredient.

 

3951

PLANTAGO AFRA

A, E, H

When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the label:

- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).

 

3952

PLANTAGO ARENARIA

A, H

When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the label:

- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).

 

3953

PLANTAGO ASIATICA

A, H

When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the label:

- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).

 

3954

PLANTAGO LANCEOLATA

A, E, H

The medicine requires the following warning statement on the medicine label:

- (CHILD5) 'Use in children under 3 years is not recommended’

When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the label:

- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).

 

3955

PLANTAGO MAJOR

A, E, H

When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the label:

- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).

 

3956

PLANTAGO OVATA

A, H

When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the label:

- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).

 

3957

PLANTAGO SEED DRY

A, H

When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the label:

- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).

 

3958

PLATANUS OCCIDENTALIS

A, E, H

 

3959

PLATANUS RACEMOSA

A, H

 

3960

PLATANUS × HISPANICA

A, H

 

3961

PLATYCODON GRANDIFLORUS

A, E, H

 

3962

PLECTRANTHUS BARBATUS

A, E, H

 

3963

PLICATONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3964

PLUM

E

 

3965

PLUMBAGO EUROPAEA

A, H

 

3966

PLUMERIA ALBA

A, E, H

 

3967

PLUMERIA RUBRA

A, E, H

 

3968

POA NEMORALIS

A, H

 

3969

POA PRATENSIS

A, H

 

3970

PODOPHYLLUM PELTATUM

A, H

Podophyllin and podophyllotoxin are mandatory components of Podophyllum peltatum.

The concentration of podophyllin in the medicine must be no more than 1 mg/kg or 1 mg/L or 0.0001%.

The concentration of podophyllotoxin in the medicine must be no more than 10 mg/kg or 10 mg/L or 0.001%.

 

3971

POGOSTEMON CABLIN

A, E, H

 

3972

POLACRILIN

E

 

3973

POLACRILIN POTASSIUM

E

 

3974

POLAPREZINC

A

Only for use in oral medicines.

Zinc is a mandatory component of Polaprezinc.

The maximum recommended daily dose must be no more than 34 milligrams of zinc sourced from polaprezinc.

When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc.

When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label:

- (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period' (or words to that effect).

 

3975

POLIGLUSAM

A, E

The average molecular mass of poliglusam must be greater than 2 kilodaltons.

When for internal use:

(a) the maximum recommended daily dose of the medicine must not provide more than 1750 milligrams poliglusam; and

(b) the following warning statement is required on the medicine label:

- (CHITO) 'Poliglusam should be taken at least one hour after any other medication as it may reduce the effect of other medication' (or words to that effect).

When for internal use and the dosage form is a powdered preparation, the following warning statement is required on the medicine label:

- (DNTPOW) 'Do not take powder alone. Mix with food or fluid'.

When used as an excipient, only for use in topical medicines for dermal application.

 

3976

POLIGLUSAM DERIVED FROM ASPERGILLUS NIGER

A, E

When for oral use:

(a) the maximum recommended daily dose of the medicine must not provide more than 2000 mg of Poliglusam derived from Aspergillus niger;

(b) the following warning statement (or words to the same effect) is required on the medicine label:

- (CHITO) 'Poliglusam should be taken at least one hour after any other medication as it may reduce the effect of other medication.'; and

(c) if the medicine is a powdered dosage form, the following warning statement is also required on the medicine label:

- (DNTPOW) 'Do not take powder alone. Mix with food or fluid.'

When used as an excipient, Poliglusam derived from Aspergillus niger is only permitted for use in topical medicines for dermal application.

 

3977

POLLACK-LIVER OIL

A, E

Colecalciferol and Vitamin A are mandatory components of Pollack-liver oil.

When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.

When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.

When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:

- (VITA2) ‘WARNING: If you are pregnant - or considering becoming pregnant - do not take vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA4) ‘WARNING - When taken in excess of 3000 micrograms retinol equivalents - Vitamin A can cause birth defects.’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA3) ‘The recommended daily amount of Vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.’

When for internal use, the maximum recommended daily dose must be no more than 25 micrograms of Vitamin D.

 

3978

POLLEN

E

The medicine requires the following warning statement on the medicine label:

- (POLLEN) 'This medicine can cause severe allergic reactions' (or words to that effect).

 

3979

POLOXAMER

E

Only for use in topical medicines for dermal application.

 

3980

POLOXAMINE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3981

POLOXAMINE 1301

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3982

POLY C10-30 ALKYL ACRYLATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2%.

 

3983

POLYACRYLAMIDE

E

Only for use in topical medicines for dermal application.

Acrylamide is a mandatory component of Polyacrylamide.

The concentration of Acrylamide in the medicine must be no more than 0.01%.

 

3984

POLYACRYLATE CROSSPOLYMER-6

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 2%.

 

3985

POLYACRYLATE-1 CROSSPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.4%.

 

3986

POLYACRYLIC ACID

E

 

3987

POLYAMINO SUGAR CONDENSATE

E

Only for use in topical medicines for dermal application.

 

3988

POLYAMINOPROPYL BIGUANIDE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.3%.

 

3989

POLYBUTADIENE

E

Only for use as part of an adhesive in topical medicines for dermal application.

 

3990

POLYBUTENE

E

Only for use in topical medicines for dermal application.

 

3991

POLYBUTYLENE GLYCOL/PPG-9/1 COPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2%.

 

3992

POLYCAPROLACTONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

3993

POLYDECENE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 6%.

 

3994

POLYDEXTROSE

E

 

3995

POLYDIETHYLSILOXANE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 5%.

 

3996

POLYDIMETHYL SILOXANE

E

Permitted for use only in combination with other permitted ingredients as a printing ink.

If used in a printing ink the total printing ink concentration in a medicine must be no more than 0.1%

 

3997

POLYESTER-10

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1.5%.

 

3998

POLYESTER-25

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 10%.

 

3999

POLYESTER-7

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4000

POLYESTER-8

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration of Polyester-8 must be no more than 5%.

 

4001

POLYETHYLENE

E

 

4002

POLYGALA CHINENSIS

A, H

 

4003

POLYGALA SENEGA

A, E, H

Except when used in a medicine containing only homoeopathic preparations, a child resistant closure and restricted flow insert must be fitted onto the container.

 

4004

POLYGALA SIBIRICA

A, E, H

Only for use when the plant part is root or root bark.

 

4005

POLYGALA TENUIFOLIA

A

Only for use when the plant part is root or root bark.

 

4006

POLYGLYCERYL-10 PENTASTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1.5%.

 

4007

POLYGLYCERYL-2 CAPRATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use on damaged skin or in the eye.

The concentration in the medicine must not be more than 0.5%.

 

4008

POLYGLYCERYL-2 DIISOSTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 3.0%.

 

4009

POLYGLYCERYL-2 DIPOLYHYDROXYSTEARATE

E

Only for use in topical medicines for dermal application. 

The concentration in the medicine must be no more than 5%.

 

4010

POLYGLYCERYL-2 DISTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 3%.

 

4011

POLYGLYCERYL-2 TRIISOSTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

When the concentration of polyglyceryl-2 triisostearate is greater than 3%, the medicine must not be intended for use on damaged skin.

The concentration in the medicine must not be more than 5%.

 

4012

POLYGLYCERYL-2-PEG-4 STEARATE

E

Only for use in topical medicines for dermal application.

 

4013

POLYGLYCERYL-3 BEESWAX

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.5%.

 

4014

POLYGLYCERYL-3 DIISOSTEARATE

E

Only for use in topical medicines for dermal application.

 

4015

POLYGLYCERYL-3 DISTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

4016

POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 6%.

 

4017

POLYGLYCERYL-3 POLYDIMETHYLSILOXYETHYL DIMETHICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5.5%.

 

4018

POLYGLYCERYL-3 POLYRICINOLEATE

E

 

4019

POLYGLYCERYL-3 STEARATE/ISOSTEARATE/DIMER DILINOLEATE CROSSPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 5%.

 

4020

POLYGLYCERYL-4 DIISOSTEARATE/POLYHYDROXYSTEARATE/SEBACATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 3%.

 

4021

POLYGLYCERYL-4 ISOSTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4022

POLYGLYCERYL-4 OLEATE

E

Only for use in topical medicines for dermal application.

 

4023

POLYGLYCERYL-6 POLYRICINOLEATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

4024

POLYGLYCERYL-6 RICINOLEATE

E

Only for use in topical medicines for dermal application.

 

4025

POLYGONATUM MULTIFLORUM

A, H

 

4026

POLYGONATUM OFFICINALE

A, H

 

4027

POLYGONATUM SIBIRICUM

A, E, H

 

4028

POLYGONUM AVICULARE

A, E, H

When used as an excipient, the medicine is only for use in topical medicines for dermal application and not to be included in medicines intended for use on damaged skin or in the eye.

When used as an excipient, the concentration in the medicine must be no more than 0.16%.

 

4029

POLYGONUM BISTORTA

A, H

 

4030

POLYGONUM ODORATUM

A, H

 

4031

POLYHYDROXYSTEARIC ACID

E

Only for use in topical medicines for dermal application.

 

4032

POLYISOBUTYLENE

E

Only for use when the dosage form is 'chewing gum'.

Must comply with:

a) the Polyisobutylene monograph in the Food Chemicals Codex published by the United States Pharmacopeial Convention, as in force or existing from time to time; and b) the requirements for residual solvents and catalysts in the British Pharmacopoeia or the United States Pharmacopeia National Formulary, as in force or existing from time to time.

 

4033

POLYISOPRENE

E

Only for use in topical medicines for dermal application.

 

4034

POLYLIMONENE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4035

POLYMETHACRYLIC ACID

E

 

4036

POLYMETHYL METHACRYLATE

E

Methyl methacrylate is a mandatory component of polymethyl methacrylate.

Only for use in topical medicines for dermal application.

The total concentration of methyl methacrylate as residual monomer in the medicine must not be more than 1%.

 

4037

POLYMETHYLSILSESQUIOXANE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 3%.

 

4038

POLYPORUS UMBELLATUS

A, H

 

4039

POLYPROPYLENE

E

Only for use in topical medicines for dermal application.

 

4040

POLYPROPYLENE GLYCOL

E

Permitted for use only in combination with other permitted ingredients as part of a flavour or fragrance proprietary excipient formulation.

When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%.

When used in a fragrance, the total fragrance proprietary excipient formulation in a medicine must be no more than 1%.

 

4041

POLYQUATERNIUM-10

E

Only for use in topical medicines for dermal application.

 

4042

POLYQUATERNIUM-11

E

Only for use in topical medicines for dermal application.

 

4043

POLYQUATERNIUM-22

E

Only for use in wash-off topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 2%.

 

4044

POLYQUATERNIUM-24

E

Only for use in topical medicines for dermal application.

 

4045

POLYQUATERNIUM-28

E

Only for use in topical medicines for dermal application.

 

4046

POLYQUATERNIUM-37

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2.5%.

 

4047

POLYQUATERNIUM-4

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 0.4%.

 

4048

POLYQUATERNIUM-44

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.3%.

 

4049

POLYQUATERNIUM-51

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4050

POLYQUATERNIUM-7

E

Only for use in topical medicines for dermal application.

 

4051

POLYSILICONE-11

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2.1%

 

4052

POLYSILICONE-14

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration of Polysilicone-14 must be no more than 1%.

 

4053

POLYSILICONE-15

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 10%.

When used in primary sunscreen products, the following warning statements are required on the label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

4054

POLYSILICONE-2

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.13%.

 

4055

POLYSORBATE 20

E

 

4056

POLYSORBATE 40

E

 

4057

POLYSORBATE 60

E

 

4058

POLYSORBATE 65

E

 

4059

POLYSORBATE 80

E

 

4060

POLYSORBATE 85

E

Only for use in topical medicines for dermal application.

 

4061

POLYSTYRENE

E

Only for use as part of an adhesive in topical medicines for dermal application.

 

4062

POLYTEF

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

4063

POLYURETHANE-34

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 2% in spray applications and 6% in non-spray applications.

 

4064

POLYURETHANE-62

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 5%.

 

4065

POLYVINYL ACETATE

E

Only permitted for use in medicines that are for oral routes of administration.

 

4066

POLYVINYL ACETATE PHTHALATE

E

 

4067

POLYVINYL ALCOHOL

E

 

4068

POLYVINYL CHLORIDE

E

Only for use in topical medicines for dermal application.

 

4069

POMEGRANATE

E

 

4070

PONCEAU SX

E

Permitted for use only as a colour for topical use.

 

4071

PONCIRUS TRIFOLIATA

A, H

When used internally, oxedrine is a mandatory component of Poncirus trifoliata.

The quantity of Oxedrine in the maximum recommended daily dose must be no more than 30 mg.

 

4072

PONGAMOL

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

4073

PONTEDERIA CRASSIPES

A, H

 

4074

POPPY SEED

E, H

 

4075

POPPY SEED OIL

E, H

 

4076

POPULUS ALBA

A, H

 

4077

POPULUS BALSAMIIFERA

A, E, H

 

4078

POPULUS CANDICANS

A, H

 

4079

POPULUS DELTOIDES

A, H

 

4080

POPULUS NIGRA

A, H

 

4081

POPULUS TREMULA

A, H

 

4082

POPULUS TREMULOIDES

A, H

 

4083

PORCINE

H

Only for use as an active homoeopathic ingredient. 

 

4084

PORPHYRIDIUM PURPUREUM EXTRACT

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

4085

PORTULACA OLERACEA

A, E, H

 

4086

POTABLE WATER

E

 

4087

POTASSIUM ACETATE

E

 

4088

POTASSIUM ARSENITE

H

Only for use as an active homoeopathic ingredient.

 

4089

POTASSIUM ASCORBATE

A, E, H

When for oral or sublingual use, potassium is a mandatory component of potassium ascorbate.

 

4090

POTASSIUM ASCORBATE DIHYDRATE

A, E, H

When for oral or sublingual use, potassium is a mandatory component of potassium ascorbate dihydrate.

 

4091

POTASSIUM ASCORBYL TOCOPHERYL PHOSPHATE

E

Only for use in topical medicines for dermal application.

 

4092

POTASSIUM ASPARTATE

A, E, H

When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium aspartate.

 

4093

POTASSIUM ASPARTATE DIHYDRATE

A, E, H

If used as an active ingredient and the preparation is intended as a mineral supplementation, potassium is a mandatory component of Potassium aspartate dihydrate. The percentage of potassium from potassium aspartate dihydrate should be calculated based on the molecular weight of potassium aspartate dihydrate.

 

4094

POTASSIUM ASPARTATE MONOHYDRATE

A, E

If used as an active ingredient and the preparation is intended as a mineral supplementation, potassium is a mandatory component of Potassium aspartate monohydrate. The percentage of potassium from potassium aspartate monohydrate should be calculated based on the molecular weight of potassium aspartate monohydrate.

 

4095

POTASSIUM BICARBONATE

E

 

4096

POTASSIUM BROMIDE

H

Only for use as an active homoeopathic ingredient.

The total concentration of potassium bromide in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.

 

4097

POTASSIUM CARBONATE

E, H

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

 

4098

POTASSIUM CETYL PHOSPHATE

E

Only for use in topical medicines for dermal application.

 

4099

POTASSIUM CHLORIDE

A, E, H

When for oral use:

(a) potassium is a mandatory component of potassium chloride;

(b) the medicine requires the following warning statement on the medicine label:

- (POTAS1) 'If you have kidney disease or are taking heart or blood pressure medicines - consult your doctor or pharmacist before use. Keep out of reach of children.'; and

(c) except when the medicine is for use as oral rehydration therapy, the amount of potassium chloride per dosage unit must not be more than 550 mg.

Medicines containing potassium chloride for use as oral rehydration therapy, are subject to the following conditions:

(a) the medicine complies with the requirements specified in the British Pharmacopoeia, as in force or existing from time to time, for Oral Rehydration Salts;

(b) the sodium, potassium and glucose content, and total osmolarity of the solution after it has been prepared according to the instructions on the packet are consistent with the criteria specified by the World Health Organisation (WHO) and the United Nations Children's Fund (UNICEF) in the document 'Expert consultation on oral rehydration salts formulation' 18 July 2001; and

(c) the following warning statements are required on the medicine label:

- (UOAD) 'Use only as directed'

- (DIAR3) 'If diarrhoea persists, seek medical advice.'

When for dental use, the concentration of potassium chloride in the medicine must not be more than 3.75%.

 

4100

POTASSIUM CITRATE

A, E, H

When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium citrate.

 

4101

POTASSIUM COCOYL HYDROLYSED COLLAGEN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 10%.

 

4102

POTASSIUM COCOYL HYDROLYSED SOY PROTEIN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.15%.

 

4103

POTASSIUM DICHROMATE

H

Only for use as an active homoeopathic ingredient.

 

4104

POTASSIUM GLUCONATE

A, E, H

When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium gluconate.

 

4105

POTASSIUM GLYCEROPHOSPHATE

A, E, H

When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium glycerophosphate.

 

4106

POTASSIUM HYDROXIDE

E

The concentration in the medicine must be no more than 5%.

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

 

4107

POTASSIUM HYDROXYCITRATE

A, H

 

4108

POTASSIUM IODATE

A, H

Iodine is a mandatory component of potassium iodate.

The percentage of iodine from potassium iodate should be calculated based on the molecular weight of potassium iodate.

When for use in adults, the medicine must contain a daily dose of no more than 505 micrograms of potassium iodate.

When for use in children aged 1-3 years, the medicine must contain a daily dose of no more than 337 micrograms of potassium iodate.

 

4109

POTASSIUM IODIDE

A, E, H

Iodine is a mandatory component of potassium iodide.

The percentage of iodine from potassium iodide should be calculated based on the molecular weight of potassium iodide.

When for internal use, the maximum recommended daily dose of the medicine must contains less than 300 micrograms of iodine.

When for external use, the concentration of iodine in the medicine (excluding salts derivatives or iodophors) must not exceed 2.5%.

 

4110

POTASSIUM METABISULFITE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4111

POTASSIUM METAPHOSPHATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

4112

POTASSIUM NITRATE

A, H

Only for dental use.

The concentration in the medicine must be no more than 5%.

 

4113

POTASSIUM OROTATE

A, E, H

When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium orotate.

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

 

4114

POTASSIUM PYROPHOSPHATE

E

Only for oral application, dental or topical use.

Not to be included in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 3%.

 

4115

POTASSIUM SORBATE

E

 

4116

POTASSIUM STANNATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4117

POTASSIUM STEARATE

E

Only for use in topical medicines for dermal application.

 

4118

POTASSIUM SULFATE

A, E, H

When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium sulfate.

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

 

4119

POTATO STARCH

E

 

4120

POTENTILLA ANSERINA

A, H

 

4121

POTENTILLA CHINENSIS

A, H

 

4122

POTENTILLA DISCOLOR

A, H

 

4123

POTENTILLA ERECTA

A, E, H

 

4124

POTENTILLA REPTANS

A, H

 

4125

POTERIUM OFFICINALE

A, E, H

 

4126

POTERIUM SANGUISORBA

A, H

 

4127

POVIDONE

E

 

4128

POWDERED CELLULOSE

E

 

4129

PPG-1-PEG-9 LAURYL GLYCOL ETHER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4130

PPG-12/SMDI COPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2%.

 

4131

PPG-15 STEARYL ETHER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4%.

 

4132

PPG-15 STEARYL ETHER BENZOATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1.4%.

 

4133

PPG-17/IPDI/DMPA COPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or on damaged skin.

The concentration of PPG-17/IPDI/DMPA Copolymer in the medicine must be no more than 10%.

 

4134

PPG-2 LANOLIN ALCOHOL ETHER

E

Only for use in topical medicines for dermal application.

 

4135

PPG-2 MYRISTYL ETHER PROPIONATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4136

PPG-20 LANOLIN ALCOHOL ETHER

E

Only for use in topical medicines for dermal application.

 

4137

PPG-20 METHYL GLUCOSE ETHER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

4138

PPG-20 METHYL GLUCOSE ETHER DISTEARATE

E

Only for use in topical medicines for dermal application.

 

4139

PPG-3 HYDROGENATED CASTOR OIL

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. 

The concentration in the medicine must be no more than 6%.

 

4140

PPG-3 MYRISTYL ETHER

E

Only for use in topical medicines for dermal application.

 

4141

PPG-5-CETETH-20

E

Only for use in topical medicines for dermal application.

 

4142

PPG-5-LAUROMACROGOL 250

E

Only for use in topical medicines for dermal application.

 

4143

PRALINE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4144

PREGELATINISED MAIZE STARCH

E

 

4145

PREGELATINISED POTATO STARCH

E

 

4146

PREGELATINISED RICE STARCH

E

 

4147

PREGELATINISED STARCH

E

 

4148

PREGELATINISED WHEAT STARCH

E

When the route of administration is other than topical or mucosal, gluten is a mandatory component of pregelatinised wheat starch.

 

4149

PRENYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4150

PRICKLY ASH BARK DRY

A, H

 

4151

PRICKLY ASH BARK POWDER

A, H

 

4152

PRIMULA VERIS

A, E, H

 

4153

PRIMULA VULGARIS

A, E, H

 

4154

PRINSEPIA UNIFLORA

A, H

 

4155

PROBOSCIDEA PARVIFLORA

A, H

 

4156

PROGESTERONE

H

Only for use as an active homoeopathic ingredient.

The total concentration of progesterone in the medicine must not be more than 1 mg/kg or 1 mg/L or 0.0001%.

 

4157

PROLINE

A, E

 

4158

PROPAN-1-OL

E

Only for use in:

- topical medicines for dermal application; or

- in combination with other permitted ingredients as a flavour proprietary excipient formulation.

The concentration of propan-1-ol in the medicine must not be more than 18%.

When used in medicines in combination with other permitted ingredients as a flavour proprietary excipient formulation, the total flavour proprietary excipient formulation in a medicine must not be more than 5%.

 

4159

PROPANE

E

Only for use as an excipient propellant ingredient.

 

4160

PROPANEDIOL

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 10%.

 

4161

PROPENYL GUAETHOL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4162

PROPIONALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4163

PROPIONIC ACID

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4164

PROPIONYLLEVOCARNITINE HYDROCHLORIDE

A, H

 

4165

PROPOLIS

A, E

Lead is a mandatory component of Propolis.

The concentration of lead in the medicine must be no more than 0.001%.

When used topically, the medicine requires the following warning statement on the medicine label:

-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'

When used for other than for topical, the medicine requires the following warning statement on the medicine label:

- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'

 

4166

PROPOLIS BALSAM

A, E

Lead is a mandatory component of Propolis balsam.

The concentration of lead in the medicine must be no more than 0.001%.

When used topically, the medicine requires the following warning statement on the medicine label:

-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'

When used for other than for topical, the medicine requires the following warning statement on the medicine label:

- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'

 

4167

PROPOLIS DRY EXTRACT

A, E

Lead is a mandatory component of Propolis dry extract.

The concentration of lead in the medicine must be no more than 0.001%.

When used topically, the medicine requires the following warning statement on the medicine label:

-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'

When used for other than for topical, the medicine requires the following warning statement on the medicine label:

- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'

 

4168

PROPOLIS LIQUID EXTRACT

A, E

Lead is a mandatory component of Propolis liquid extract.

The concentration of lead in the medicine must be no more than 0.001%.

When used topically, the medicine requires the following warning statement on the medicine label:

-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'

When used for other than for topical, the medicine requires the following warning statement on the medicine label:

- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'

 

4169

PROPOLIS RESIN

A, E

Lead is a mandatory component of propolis resin.

The concentration of lead in the medicine must be no more than 0.001%.

When used topically, the medicine requires the following warning statement on the medicine label:

-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'

When used for other than for topical, the medicine requires the following warning statement on the medicine label:

- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'

 

4170

PROPOLIS TINCTURE

A, E

Lead is a mandatory component of Propolis tincture.

The concentration of lead in the medicine must be no more than 0.001%.

When used topically, the medicine requires the following warning statement on the medicine label:

-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'

When used for other than for topical, the medicine requires the following warning statement on the medicine label:

- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'

 

4171

PROPYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4172

PROPYL CAPROATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4173

PROPYL GALLATE

E

 

4174

PROPYL HYDROXYBENZOATE

E

 

4175

PROPYLENE CARBONATE

E

Only for use in topical medicines for dermal application.

 

4176

PROPYLENE GLYCOL

E

 

4177

PROPYLENE GLYCOL ALGINATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4178

PROPYLENE GLYCOL DIBENZOATE

E

Only for use in topical medicines for dermal application only and not to be used in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 20%.

 

4179

PROPYLENE GLYCOL DIDECANOATE

E

Only for use in topical medicines for dermal application only and not to be used in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

4180

PROPYLENE GLYCOL DIOCTANOATE

E

Only for use in topical medicines for dermal application.

 

4181

PROPYLENE GLYCOL DIOCTANOATE/DIDECANOATE

E

Only for use in topical medicines for dermal application.

 

4182

PROPYLENE GLYCOL DIPELARGONATE

E

Only for use in topical medicines for dermal application.

 

4183

PROPYLENE GLYCOL ISOCETETH-3 ACETATE

E

Only for use in topical medicines for dermal application only and not to be used in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

4184

PROPYLENE GLYCOL ISOSTEARATE

E

Only for use in topical medicines for dermal application.

 

4185

PROPYLENE GLYCOL MONOLAURATE

E

Only for use in topical medicines for dermal application.

 

4186

PROPYLENE GLYCOL MONOSTEARATE

E

Only for use in topical medicines for dermal application.

 

4187

PROPYLENE GLYCOL MYRISTYL ETHER ACETATE

E

Only for use in topical medicines for dermal application.

 

4188

PROSOPIS JULIFLORA

A, H

 

4189

PROTEASE

A

Must be derived from Aspergillus oryzae or Aspergillus niger.

 

4190

PROTEIN HYDROLYSATE

E

 

4191

PRUNE JUICE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4192

PRUNE JUICE CONCENTRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4193

PRUNELLA VULGARIS

A, H

 

4194

PRUNUS AFRICANA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus africana.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4195

PRUNUS ARMENIACA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus armeniaca and must be declared in the application.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4196

PRUNUS AVIUM

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus avium.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4197

PRUNUS CERASIFERA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus cerasifera.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4198

PRUNUS CERASUS

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus cerasus.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4199

PRUNUS DOMESTICA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus domestica.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4200

PRUNUS DULCIS

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus dulcis when the plant part is seed.

When the plant part is seed, the maximum recommended daily dose must be no more than the equivalent of 1mg of the dry seed.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4201

PRUNUS HUMILIS

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus humilis.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4202

PRUNUS JAPONICA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus japonica.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4203

PRUNUS LAUROCERASUS

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus laurocerasus.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4204

PRUNUS MUME

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus mume.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4205

PRUNUS PERSICA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus persica.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4206

PRUNUS SALICINA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus salicina.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4207

PRUNUS SEROTINA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus serotina.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4208

PRUNUS SPINOSA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus spinosa.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4209

PRUSSIAN BLUE

E

Permitted for use only as a colour for topical use.

 

4210

PSEUDOCYDONIA SINENSIS

A, H

 

4211

PSEUDOSTELLARIA HETEROPHYLLA

A, E, H

 

4212

PSEUDOTSUGA MENZIESII

A, H

 

4213

PSEUDOWINTERA COLORATA

A, H

Only for use when the plant part is leaf.

 

4214

PSIDIUM GUAJAVA

A, E, H

 

4215

PSORINUM

H

Only for use as an active homoeopathic ingredient. 

 

4216

PSYLLIUM HUSK DRY

A, H

When a dose for children is stated, the following warning statement is required on the label:

- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).

 

4217

PSYLLIUM HUSK POWDER

A, E, H

When a dose for children is stated, the following warning statement is required on the label:

- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).

 

4218

PSYLLIUM SEED DRY

A, E, H

When a dose for children is stated the following warning statement is required on the label:

- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).

 

4219

PTELEA TRIFOLIATA

A, H

 

4220

PTEROCARPUS MARSUPIUM

A, H

 

4221

PTEROCARPUS SANTALINUS

A, E, H

 

4222

PUERARIA LOBATA

A, E, H

 

4223

PUERARIA MONTANA VAR. LOBATA

A, E, H

 

4224

PULLULAN

E

 

4225

PUMICE

E

 

4226

PUMPKIN

E

 

4227

PUMPKIN SEED

E, H

 

4228

PUMPKIN SEED OIL

E, H

 

4229

PUNICA GRANATUM

A, E, H

 

4230

PURE BEE VENOM

H

Only for use as an active homoeopathic ingredient.

 

4231

PURIFIED HONEY

A, E

When the route of administration is oral, the following warning statement is required on the medicine label:

- (BABY2) 'Not suitable for infants under the age of twelve months' (or words to that effect).

 

4232

PURIFIED SILICEOUS EARTH

E, H

 

4233

PURIFIED TALC

E

 

4234

PURIFIED WATER

E

 

4235

PVM/MA COPOLYMER

E

 

4236

PVM/MA DECADIENE CROSSPOLYMER

E

Only for use in topical medicines for dermal application.

 

4237

PVP/EICOSENE COPOLYMER

E

Only for use in topical medicines for dermal application.

 

4238

PVP/HEXADECENE COPOLYMER

E

Only for use in topical medicines for dermal application.

 

4239

PYRETHRINS

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 10%.

The medicine requires the following warning statement on the medicine label:

- (PYRTH3) 'Contains pyrethrins [insert quantity]' (or words to that effect).

 

4240

PYRIDOXAL 5-PHOSPHATE

A, E

Pyridoxine is a mandatory component of Pyridoxal 5-phosphate.

The percentage of pyridoxine from pyridoxal 5-phosphate should be calculated based on the molecular weight of pyridoxal 5-phosphate.

The requirements specified in paragraphs (a) to (b) below apply to a medicine that contains the ingredient that is:

- listed in the Register before 1 March 2022; and

- released for supply before 1 March 2023.

(a) The maximum recommended daily dose must provide no more than 200 mg of pyridoxine.

(b) If the medicine contains more than 50 mg and no more than 200 mg of pyridoxine per maximum recommended daily dose the medicine requires the following warning statement on the medicine label:

- (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].'

The requirements specified in paragraphs (c) to (d) below apply to a medicine that contains the ingredient that is:

- listed in the Register on or after 1 March 2022; or

- released for supply on or after 1 March 2023.

(c) The maximum recommended daily dose of the medicine must not provide more than:

(i) 15 mg of pyridoxine for children aged between 1 and 3 years (inclusive);

(ii) 20 mg of pyridoxine for children aged between 4 and 8 years (inclusive);

(iii) 30 mg of pyridoxine for children aged between 9 and 13 years (inclusive);

(iv) 40 mg of pyridoxine for individuals aged 14 and 18 years (inclusive); and

(v) 100 mg of pyridoxine for individuals aged 19 years and older.

(d) If the maximum recommended daily dose of the medicine provides more than 10 mg of pyridoxine, the following warning statement is required on the medicine label:

- (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].'

 

4241

PYRIDOXAL 5-PHOSPHATE MONOHYDRATE

A

Pyridoxine is a mandatory component of Pyridoxal 5-phosphate monohydrate.

The percentage of pyridoxine from pyridoxal 5-phosphate monohydrate should be calculated based on the molecular weight of pyridoxal 5-phosphate monohydrate.

The requirements specified in paragraphs (a) to (b) below apply to a medicine that contains the ingredient that is:

- listed in the Register before 1 March 2022; and

- released for supply before 1 March 2023.

(a) The maximum recommended daily dose must provide no more than 200 mg of pyridoxine.

(b) If the medicine contains more than 50 mg and no more than 200 mg of pyridoxine per maximum recommended daily dose the medicine requires the following warning statement on the medicine label:

- (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].'

The requirements specified in paragraphs (c) to (d) below apply to a medicine that contains the ingredient that is:

- listed in the Register on or after 1 March 2022; or

- released for supply on or after 1 March 2023.

(c) The maximum recommended daily dose of the medicine must not provide more than:

(i) 15 mg of pyridoxine for children aged between 1 and 3 years (inclusive);

(ii) 20 mg of pyridoxine for children aged between 4 and 8 years (inclusive);

(iii) 30 mg of pyridoxine for children aged between 9 and 13 years (inclusive);

(iv) 40 mg of pyridoxine for individuals aged 14 and 18 years (inclusive); and

(v) 100 mg of pyridoxine for individuals aged 19 years and older.

(d) If the maximum recommended daily dose of the medicine provides more than 10 mg of pyridoxine, the following warning statement is required on the medicine label:

- (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].'

 

4242

PYRIDOXINE HYDROCHLORIDE

A, E, H

When not used as an active homoeopathic ingredient, pyridoxine is a mandatory component of Pyridoxine hydrochloride.

The percentage of pyridoxine from pyridoxine hydrochloride should be calculated based on the molecular weight of pyridoxine hydrochloride.

The requirements specified in paragraphs (a) to (b) below apply to a medicine that contains the ingredient that is:

- listed in the Register before 1 March 2022; and

- released for supply before 1 March 2023.

(a) The maximum recommended daily dose must provide no more than 200 mg of pyridoxine.

(b) If the medicine contains more than 50 mg and no more than 200 mg of pyridoxine per maximum recommended daily dose the medicine requires the following warning statement on the medicine label:

- (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].'

The requirements specified in paragraphs (c) to (d) below apply to a medicine that contains the ingredient that is:

- listed in the Register on or after 1 March 2022; or

- released for supply on or after 1 March 2023.

(c) The maximum recommended daily dose of the medicine must not provide more than:

(i) 15 mg of pyridoxine for children aged between 1 and 3 years (inclusive);

(ii) 20 mg of pyridoxine for children aged between 4 and 8 years (inclusive);

(iii) 30 mg of pyridoxine for children aged between 9 and 13 years (inclusive);

(iv) 40 mg of pyridoxine for individuals aged 14 and 18 years (inclusive); and

(v) 100 mg of pyridoxine for individuals aged 19 years and older.

(d) If the maximum recommended daily dose of the medicine provides more than 10 mg of pyridoxine, the following warning statement is required on the medicine label:

- (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].'

 

4243

PYROGLUTAMIC ACID

E

 

4244

PYROLA DECORATA

A, H

 

4245

PYROLIGNEOUS ACID

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4246

PYRROSIA LINGUA

A, H

 

4247

PYRROSIA PETIOLOSA

A, H

 

4248

PYRROSIA SHEARERI

A, H

 

4249

PYRUS COMMUNIS

A, E, H

Beta-arbutin is a mandatory component of Pyrus communis.

When for oral use, the maximum recommended daily dose must not provide more than 500 mg of beta-arbutin.

When for dermal application exclusively to the face:

a) the concentration of beta-arbutin in the medicine must not be more than 7%; 

b) hydroquinone is a mandatory component; and

c) the concentration of hydroquinone must not be more than 10 mg/kg or 10 mg/L or 0.001%.

When for use other than oral or dermal application exclusively to the face, the concentration of beta-arbutin in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.

 

4250

PYRUS PYRIFOLIA

A, H

Beta-arbutin is a mandatory component of Pyrus pyrifolia.

When for oral use, the maximum recommended daily dose must not provide more than 500 mg of beta-arbutin.

When for dermal application exclusively to the face:

a) the concentration of beta-arbutin in the medicine must not be more than 7%;

b) hydroquinone is a mandatory component; and

c) the concentration of hydroquinone must not be more than 10 mg/kg or 10 mg/L or 0.001%.

When for use other than oral or dermal application exclusively to the face, the concentration of beta-arbutin in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.

 

4251

PYRUVIC ACID

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4252

QUASSIA

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4253

QUASSIA AMARA

A, E, H

 

4254

QUASSIA WOOD JAMAICAN DRY

A, H

 

4255

QUASSIA WOOD JAMAICAN POWDER

A, H

 

4256

QUATERNIUM-15

E

Only for use in topical medicines for dermal application.

 

4257

QUATERNIUM-18 BENTONITE

E

Only for use in topical medicines for dermal application.

 

4258

QUATERNIUM-18 HECTORITE

E

Only for use in topical medicines for dermal application.

 

4259

QUATERNIUM-52

E

Only for use in wash-on/wash-off topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

Not be used in medicines in which N-nitroso compounds may be formed.

 

4260

QUATERNIUM-80

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2.5%.

 

4261

QUERCETIN

A

 

4262

QUERCETIN DIHYDRATE

A

 

4263

QUERCUS ACUTISSIMA

A, H

 

4264

QUERCUS ALBA

A, E, H

 

4265

QUERCUS PALUSTRIS

A, H

 

4266

QUERCUS ROBUR

A, H

 

4267

QUERCUS RUBRA

A, H

 

4268

QUERCUS VIRGINIANA

A, H

 

4269

QUILLAIA DRY

A, H

 

4270

QUILLAIA POWDER

A, E, H

 

4271

QUILLAJA SAPONARIA

A, H

 

4272

QUINCE

E

 

4273

QUININE ARSENITE

H

Only for use as an active homoeopathic ingredient.

Quinine is a mandatory component of Quinine arsenite.

The maximum recommended daily dose must be no more than 50 mg of quinine.

 

4274

QUININE SULFATE DIHYDRATE

H

Only for use as an active homoeopathic ingredient. 

Quinine is a mandatory component of quinine sulfate dihydrate. 

The maximum recommended daily dose must be no more than 50 mg of quinine.

 

4275

QUINOLINE YELLOW

E

Permitted for use only as a colour for oral and topical use.

 

4276

QUINOLINE YELLOW ALUMINIUM LAKE

E

Permitted for use only as a colour for oral and topical use.

 

4277

QUISQUALIS INDICA

A, H

 

4278

R-ALPHA LIPOIC ACID

A

 

4279

RACEMENTHOL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4280

RACEMIC CAMPHOR

E, H

Only for use as an active homoeopathic or excipient ingredient.

In solid and semi solid preparations, the concentration of camphor must be no more than 12.5%.

In liquid preparations other than essential oils, the concentration of camphor must be no more than 2.5%.

In essential oil preparations, if the concentration of camphor is more than 2.5% but less than or equal to 10%, and the nominal capacity of the container is less than 25 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is less than 15 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, the medicine must have a restricted flow insert and child resistant closure fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

If the concentration of camphor is more than 2.5%, the nominal capacity of the container must be no more than 25 millilitres.

 

4281

RADISH

E

 

4282

RAISIN JUICE CONCENTRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4283

RANUNCULUS BULBOSUS

A, H

 

4284

RANUNCULUS FICARIA

A, H

 

4285

RANUNCULUS TERNATUS

A, H

 

4286

RAPE SEED OIL

A, E, H

Allyl isothiocyanate is a mandatory component of rape seed oil when the plant part is seed.

The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.

 

4287

RAPHANUS SATIVUS

A, H

 

4288

RASPBERRY

E

 

4289

RASPBERRY BRANDY

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4290

RASPBERRY DISTILLATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4291

RASPBERRY FRUIT EXTRACT

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4292

RASPBERRY JUICE CONCENTRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4293

RAUWOLFIA SERPENTINA

A, H

The concentration of equivalent dry Rauwolfia serpentina in the medicine must be no more than 10mg/Kg or 10mg/L or 0.001%.

 

4294

RAUWOLFIA SERPENTINA DRY

A, H

The concentration of Rauwolfia Serpentina Dry in the medicine must be no more than 10mg/Kg or 10mg/L or 0.001%.

 

4295

RAUWOLFIA SERPENTINA POWDER

A, H

The concentration of Rauwolfia Serpentina Powder in the medicine must be no more than 10mg/Kg or 10mg/L or 0.001%.

 

4296

RED 27

E

Permitted for use only as a colour in medicines limited to topical and oral routes of administration.

The concentration in the medicine must be no more than 0.5%.

 

4297

RED 27 ALUMINIUM LAKE

E

Permitted for use only as a colour in medicines limited to topical and oral routes of administration.

The concentration in the medicine must be no more than 0.5%.

 

4298

RED ANT

H

Only for use as an active homoeopathic ingredient.

 

4299

RED CLOVER FLOWER DRY

A, H

 

4300

RED CLOVER FLOWER POWDER

A, H

 

4301

RED CORAL

H

Only for use as an active homoeopathic ingredient.

 

4302

RED DEER

A

 

4303

RED MERCURIC IODIDE

H

Only for use as an active homoeopathic ingredient.

 

4304

RED MERCURIC OXIDE

H

Only for use as an active homoeopathic ingredient.

 

4305

RED MERCURIC SULFIDE

H

Only for use as an active homoeopathic ingredient.

 

4306

REHMANNIA GLUTINOSA

A, E, H

 

4307

REL-1-((1R,2S)-1,2,3,4,5,6,7,8-OCTAHYDRO-1,2,8,8-TETRAMETHYL-2-NAPHTHALENYL)-1-ETHANONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4308

RESORCINOL

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4309

RESORCINOL DIMETHYLETHER

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4310

RESVERATROL

A

Only permitted for use in medicines that are for oral routes of administration.

The maximum recommended daily dose of the medicine must not contain more than 150 milligrams of resveratrol.

The following warning statements are required on the medicine label:

- (RESVER) 'Resveratrol may affect the way some medicines work, including Warfarin. Consult your health professional before taking with other medicines (or words to that effect).';

- (PREGNT) ‘Not recommended for use by pregnant and lactating women’ (or words to that effect)’; and

- (CHILD2) ‘Not suitable for children’.

 

4311

RETINOL

A, E

Vitamin A is a mandatory component of retinol.

When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.

When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.

When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:

- (VITA2) ‘WARNING: If you are pregnant - or considering becoming pregnant - do not take Vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA4) ‘WARNING - When taken in excess of 3000 micrograms retinol equivalents - Vitamin A can cause birth defects.’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA3) ‘The recommended daily amount of Vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.’

 

4312

RETINOL ACETATE

A, E

Vitamin A is a mandatory component of retinol acetate.

When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.

When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.

When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:

- (VITA2) ‘WARNING: If you are pregnant - or considering becoming pregnant - do not take Vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA4) ‘WARNING - When taken in excess of 3000 micrograms retinol equivalents - Vitamin A can cause birth defects.’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA3) ‘The recommended daily amount of Vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.’

 

4313

RETINOL PALMITATE

A, E

Vitamin A is a mandatory component of retinol palmitate.

When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.

When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.

When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:

- (VITA2) ‘WARNING: If you are pregnant - or considering becoming pregnant - do not take Vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA4) ‘WARNING - When taken in excess of 3000 micrograms retinol equivalents - Vitamin A can cause birth defects.’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA3) ‘The recommended daily amount of Vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.’

 

4314

REYNOUTRIA JAPONICA

A, E, H

When used as an excipient, only for use in topical medicines for dermal application.

 

4315

RHAMNOSE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4316

RHAMNUS CATHARTICA

A, H

When the route of administration is oral, Hydroxyanthracene derivatives is a mandatory component of Rhamnus cathartica.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4317

RHAMNUS FRANGULA

A, H

Glucofrangulins calculated as glucofrangulin A is a mandatory component of Rhamnus frangula.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4318

RHATANY ROOT DRY

A, H

 

4319

RHATANY ROOT POWDER

A, H

 

4320

RHEUM OFFICINALE

A, E, H

The plant part must not be leaf.

When the route of administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of Rheum officinale.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4321

RHEUM PALMATUM

A, E, H

The plant part must not be leaf.

When the route of administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of Rheum palmatum.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) ‘Use in children under 12 years is not recommended’;

- (LAX2) ‘Prolonged use may cause serious bowel problems’; and

- (LAX3) ‘Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) ‘Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) ‘This product contains [name of the herb(s) or the chemical component(s)]’; and

- (LAX4) ‘This product may have laxative effect’.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) ‘Use in children under 12 years is not recommended’;

- (LAX1) ‘Drink plenty of water' (or words to that effect); and

- (LAX2) ‘Prolonged use may cause serious bowel problems’.

 

4322

RHEUM RHAPONTICUM

A, E, H

The plant part must not be leaf.

When the route of administration is oral, Hydroxyanthracene derivatives is a mandatory component of Rheum rhaponticum.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4323

RHEUM TANGUTICUM

A, H

The plant part must not be leaf.

When the route of administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of Rheum tanguticum.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4324

RHODAMINE B

E

Permitted for use only as a colour for topical use.

 

4325

RHODINOL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4326

RHODINYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used as a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4327

RHODIOLA ROSEA

A

Only for use in oral medicines.

Only available for use when the plant preparation is dry root powder, dry root powder as an aqueous extract or dry root powder as a hydroethanolic extract with no more than 70% ethanol v/v.

 

4328

RHODODENDRON AUREUM

A, H

 

4329

RHODODENDRON FERRUGINEUM

A, H

Beta-arbutin is a mandatory component of Rhododendron ferrugineum.

When for oral use, the maximum recommended daily dose must not provide more than 500 mg of beta-arbutin.

When for dermal application exclusively to the face:

a) the concentration of beta-arbutin in the medicine must not be more than 7%;

b) hydroquinone is a mandatory component; and

c) the concentration of hydroquinone must not be more than 10 mg/kg or 10 mg/L or 0.001%.

When for use other than oral or dermal application exclusively to the face, the concentration of beta-arbutin in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.

 

4330

RHODODENDRON GROENLANDICUM

A, H

 

4331

RHODODENDRON MOLLE

A, H

The maximum recommended daily dose of the medicine must be no more than 1mg of the dry herbal material.

 

4332

RHUBARB

E, H

When the route of administration is oral, Hydroxyanthracene derivatives is a mandatory component of Rhubarb.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4333

RHUBARB ROOT DRY

A, H

When the route of administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of rhubarb root dry.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4334

RHUBARB ROOT POWDER

A, H

When the route of administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of rhubarb root powder.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4335

RHUS AROMATICA

A, E, H

 

4336

RHUS CHINENSIS

A, H

 

4337

RHUS GLABRA

A, E, H

 

4338

RHUS VENENATA

H

Only for use as an active homoeopathic ingredient.

 

4339

RIBES GROSSULARIA

A, E, H

 

4340

RIBES NIGRUM

A, E, H

 

4341

RIBOFLAVIN

A, E

 

4342

RIBOFLAVIN SODIUM PHOSPHATE

A, E

 

4343

RIBOFLAVIN TETRAACETATE

E

Only for use in topical medicines for dermal application.

 

4344

RIBOFLAVINE

A, E

 

4345

RIBOFLAVINE SODIUM PHOSPHATE

A, E

 

4346

RIBONUCLEIC ACID

E

Only for use in topical medicines for dermal application.

 

4347

RIBOSE

A

Only for use in oral medicines.

 

4348

RICE

E

 

4349

RICE BRAN

E

 

4350

RICE BRAN OIL

E

 

4351

RICE BRAN WAX

A, E, H

 

4352

RICE STARCH

E

 

4353

RICE VINEGAR

E

 

4354

RICE WINE

E

Ethanol is a mandatory component of rice wine.

 

4355

RICINOLEIC ACID

E

Only for use in topical medicines for dermal application.

 

4356

RICINUS COMMUNIS

A, H

Only for use when the plant part must be seed and the plant preparation is oil fixed.

 

4357

ROBINIA PSEUDOACACIA

A, E, H

When the herbal substance is derived from plant parts other than the leaf or flower, the maximum recommended daily dose of the medicine must be no more than 1mg of the dry herbal material.

 

4358

ROHDEA JAPONICA

A, H

The maximum recommended daily dose must be no more than the equivalent of 1mg of the dry herbal material.

 

4359

ROSA ARVENSIS

A, E, H

 

4360

ROSA CANINA

A, E, H

 

4361

ROSA CYMOSA

A, E, H

 

4362

ROSA EGLANTERIA

A, E, H

 

4363

ROSA GALLICA

A, E, H

 

4364

ROSA LAEVIGATA

A, E, H

 

4365

ROSA MULTIFLORA

A, E, H

 

4366

ROSA ROXBURGHII FRUIT EXTRACT

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.002%.

 

4367

ROSA RUGOSA

A, E, H

 

4368

ROSA VILLOSA

A, E, H

 

4369

ROSA X CENTIFOLIA

A, E, H

 

4370

ROSA X DAMASCENA

A, E, H

 

4371

ROSANA

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4372

ROSE ABSOLUTE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4373

ROSE FRUIT FRESH

A, E, H

 

4374

ROSE HIP

E

 

4375

ROSE OIL

A, E, H

 

4376

ROSE OXIDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4377

ROSEMARY OIL

A, E, H

Safrole is a mandatory component of Rosemary oil.

When for internal use then the concentration of safrole in the medicine must be no more than 0.1%.

When for topical use then the concentration of safrole in the medicine must be no more than 1%.

 

4378

ROSMARINUS OFFICINALIS

A, E, H

Camphor and cineole are mandatory components of Rosmarinus officinalis.

In solid and semi solid preparations, the concentration of camphor must be no more than 12.5%.

In liquid preparations other than essential oils or distillates, the concentration of camphor must be no more than 2.5%.

When the concentration of cineole in the preparation is more than 25%, the nominal capacity of the container must not be more than 25 millilitres.

In liquid preparations other than essential oils or distillates, when the concentration of cineole in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, the medicine must have a child resistant closure and restricted flow insert fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

In liquid preparations other than essential oils or distillates, when the concentration of cineole in the preparation is more than 25% and the nominal capacity of the container is no more than 15 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

If the concentration of camphor is more than 2.5%, the nominal capacity of the container must be no more than 25 millilitres.

 

4379

ROYAL JELLY

A, E

10-Hydroxy-2-decenoic acid is a mandatory component of Royal jelly.

The medicine requires the following warning statements on the medicine label:

- (CHILD2) 'Not suitable for children'

- (ROYJ) 'Not to be taken by asthma and allergy sufferers' in 3 mm type, prominent on front and 'This product contains royal jelly which has been reported to cause severe allergic reactions and in rare cases fatalities, especially in asthma and allergy sufferers'.

 

4380

ROYAL JELLY FRESH

A, E

10-Hydroxy-2-decenoic acid is a mandatory component of Royal jelly fresh.

The medicine requires the following warning statements on the medicine label:

- (CHILD2) 'Not suitable for children'

- (ROYJ) 'Not to be taken by asthma and allergy sufferers' in 3 mm type, prominent on front and 'This product contains royal jelly which has been reported to cause severe allergic reactions and in rare cases fatalities, especially in asthma and allergy sufferers'.

 

4381

ROYAL JELLY LYOPHILISED

A, E

10-Hydroxy-2-decenoic acid is a mandatory component of Royal jelly lyophilised.

The medicine requires the following warning statements on the medicine label:

- (CHILD2) 'Not suitable for children'

- (ROYJ) 'Not to be taken by asthma and allergy sufferers' in 3 mm type, prominent on front and 'This product contains royal jelly which has been reported to cause severe allergic reactions and in rare cases fatalities, especially in asthma and allergy sufferers'.

 

4382

RUBBER NATURAL

E

Only for use in topical medicines for dermal application.

 

4383

RUBIA CORDIFOLIA

A, H

 

4384

RUBIA TINCTORUM

A, H

 

4385

RUBUS CHINGII

A, H

 

4386

RUBUS CORCHORIFOLIUS

A, H

 

4387

RUBUS COREANUS

A, E, H

 

4388

RUBUS FRUTICOSUS

A, E, H

 

4389

RUBUS IDAEUS

A, E, H

 

4390

RUBUS OCCIDENTALIS

A, E, H

 

4391

RUBUS PARVIFOLIUS

A, H

 

4392

RUBUS ROSIFOLIUS

A, H

 

4393

RUDBECKIA HIRTA

A, H

 

4394

RUE OIL

A, H

 

4395

RUM

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4396

RUMEX ACETOSA

A, H

 

4397

RUMEX ACETOSELLA

A, H

 

4398

RUMEX CONGLOMERATUS

A, H

 

4399

RUMEX CRISPUS

A, E, H

 

4400

RUMEX PULCHER

A, H

 

4401

RUMEX SCUTATUS

A, H

 

4402

RUSCUS ACULEATUS

A, H

 

4403

RUTA GRAVEOLENS

A, E, H

 

4404

RUTOSIDE

A, E

 

4405

RYE

E

Gluten is a mandatory component of Rye when the route of administration is other than topical and mucosal.

 

4406

RYE BRAN

E

Gluten is a mandatory component of Rye bran when the route of administration is other than topical and mucosal.

 

4407

S-ISOPROPYL 3-METHYLTHIOCROTONATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4408

SABINENE

E

Sabinene must only be included in medicines when in combination with other permitted ingredients as a flavour proprietary excipient formulation.

The total concentration of flavour proprietary excipient formulations containing sabinene must not be more than 5% of the total medicine.

 

4409

SABINENE HYDRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4410

SACCHARIDE ISOMERATE

E

Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 3.66%.

 

4411

SACCHARIN

E

 

4412

SACCHARIN SODIUM

E

 

4413

SACCHAROMYCES CEREVISIAE

A, E

When for topical use, the concentration in the medicine must be no more than 1%.

 

4414

SACCHAROMYCES CEREVISIAE (BOULARDII)

A

 

4415

SACCHAROMYCES CERVISIAE POLYSACCHARIDES

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

4416

SACCHAROMYCES/ZINC FERMENT

E

Only for use in topical medicines for dermal application.

 

4417

SACCHARUM OFFICINARUM

A, E, H

 

4418

SAFFLOWER OIL

A, E, H

 

4419

SAFFRON

E

Permitted for use only as a colour for either topical use or with an oral route of administration.

 

4420

SAGE LEAF DRY

A, E, H

Thujone is a mandatory component of Sage leaf dry.

The concentration of thujone in the medicine must be no more than 4%.

 

4421

SAGE LEAF POWDER

A, H

Thujone is a mandatory component of Sage leaf powder.

The concentration of thujone in the medicine must be no more than 4%.

 

4422

SAGE OIL DALMATIAN

A

Thujone is a mandatory component of Sage oil dalmatian.

The concentration of thujone in the medicine must be no more than 4%.

When the concentration of Sage oil dalmatian in the medicine is more than 10% and the nominal capacity of the container is no more than 15 mL, a restricted flow insert and child resistant closure must be  fitted on the container and the medicine requires the following warning statements on the medicine label:

- (CHILD) ‘Keep out of reach of children’ (or word to that effect)

- (NTAKEN) ‘Not to be taken’

 

4423

SAGE OIL SPANISH

A, E, H

 

4424

SALICORNIA EUROPAEA EXTRACT

E

Only for use in topical medicines for dermal use and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.002%.

 

4425

SALICYLALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4426

SALICYLIC ACID

E, H

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 40%.

 

4427

SALIX ALBA

A, E, H

 

4428

SALIX DAPHNOIDES

A, H

 

4429

SALIX DISCOLOR

A, H

 

4430

SALIX FRAGILIS

A, H

 

4431

SALIX NIGRA

A, H

 

4432

SALIX PURPUREA

A, H

 

4433

SALSOLA KALI

A, H

 

4434

SALVIA CHINENSIS

A, H

 

4435

SALVIA FRUTICOSA

A, H

 

4436

SALVIA HISPANICA

A, E, H

 

4437

SALVIA LAVANDULAEFOLIA

A, H

 

4438

SALVIA MILTIORRHIZA

A, H

 

4439

SALVIA OFFICINALIS

A, E, H

Thujone is a mandatory component of Salvia officinalis.

The concentration of thujone in the medicine must be no more than 4%.

 

4440

SALVIA SCLAREA

A, E, H

 

4441

SAMBUCUS CANADENSIS

A, H

 

4442

SAMBUCUS EBULUS

A, H

 

4443

SAMBUCUS NIGRA

A, E, H

 

4444

SANDALWOOD OIL EAST INDIAN

A, E, H

 

4445

SANGUINARIA CANADENSIS

H

Only for use as an active homoeopathic ingredient.

The potency must be more than 4X.

 

4446

SANICULA EUROPAEA

A, H

 

4447

SANTALUM ALBUM

A, E, H

 

4448

SANTALUM SPICATUM

A, E, H

The route of administration must be topical or inhalation.

The plant preparation must be oil.

The plant part must be root or stem wood including heartwood.

 

4449

SAPINDUS MUKOROSSI

A, H

 

4450

SAPONARIA OFFICINALIS

A, H

 

4451

SAPOSHNIKOVIA DIVARICATA

A, H

 

4452

SARCOSINE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

4453

SARGASSUM FUSIFORME

A, H

Iodine is a mandatory component of Sargassum fusiforme.

Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less.

Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.

 

4454

SARGASSUM SILIQUASTRUM

A, H

Iodine is a mandatory component of Sargassum siliquastrum.

Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less.

Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.

 

4455

SASSAFRAS ALBIDUM

A, H

Safrole is a mandatory component of Sassafras albidum.

When for internal use then the concentration of safrole in the medicine must be no more than 0.1%.

When for topical use then the concentration of safrole in the medicine must be no more than 1%.

 

4456

SATUREIA HORTENSIS

A, H

 

4457

SATUREIA MONTANA

A, H

 

4458

SAUROPUS SPATULIFOLIUS

A, H

 

4459

SAURURUS CHINENSIS

A, H

 

4460

SAUSSUREA COSTUS

A, H

 

4461

SAVORY OIL SUMMER

A, H

 

4462

SAXIFRAGA GRANULATA

A, E, H

 

4463

SAXIFRAGA STOLONIFERA

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 0.0816%.

 

4464

SCAPHIUM SCAPHIGERUM

A, H

 

4465

SCHEFFLERA HEPTAPHYLLA

A, H

 

4466

SCHINOPSIS QUEBRACHO-COLORADO

A, H

 

4467

SCHINUS MOLLE

A, H

 

4468

SCHINUS MOLLE OIL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4469

SCHISANDRA CHINENSIS

A, E, H

 

4470

SCHIZONEPETA TENUIFOLIA

A, E, H

 

4471

SCHOENOCAULON OFFICINALE

A, H

The maximum recommended daily dose of the medicine must not contain more than the equivalent of 1 mg of the dry herbal material.

The concentration of total alkaloids of Schoenocaulon officinale in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.

 

4472

SCLAREOL

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4473

SCLAREOLIDE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4474

SCLERANTHUS ANNUUS

A, H

 

4475

SCLEROTIUM GUM

E

Only for use in topical medicines for dermal application.

 

4476

SCOPOLIA CARNIOLICA

A, H

The concentration of equivalent dry Scopolia carniolica in the medicine must be no more than 10mg/Kg or 10mg/L or 0.001%.

 

4477

SCROPHULARIA NINGPOENSIS

A, H

 

4478

SCROPHULARIA NODOSA

A, H

 

4479

SCURRULA PARASITICA VAR. GRACILIFLORA

A, H

 

4480

SCUTELLARIA BAICALENSIS

A, E, H

 

4481

SCUTELLARIA BARBATA

A, H

 

4482

SCUTELLARIA LATERIFLORA

A, E, H

 

4483

SEA WHIP EXTRACT

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.02%.

 

4484

SEC BUTYL 3-METHYLBUT-2-ENETHIOATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4485

SEC-BUTYL THIOISOVALERATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4486

SECALE CEREALE

A, H

Gluten is a mandatory component of Secale cereale when the plant part is seed and the route of administration is other than topical and mucosal.

 

4487

SEDUM ACRE

A, H

 

4488

SELAGINELLA TAMARISCINA

A, H

 

4489

SELENICEREUS GRANDIFLORUS

A, E, H

 

4490

SELENIUM

H

Only for use as an active homoeopathic ingredient.

Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.

When for oral use, the medicine requires the following warning statement on the medicine label:

- (SELE) 'This medicine contains selenium which is toxic in high doses.

A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.'

 

4491

SELENOCYSTEINE

A

Selenium is a mandatory component of Selenocysteine for oral and sublingual use.

Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.

When for oral use, the medicine requires the following warning statement on the medicine label:

- (SELE) 'This medicine contains selenium which is toxic in high doses.

 A daily dose of 150 mcg for adults of selenium from dietary supplements should not be exceeded.'

 

4492

SELENOMETHIONINE

A

Selenium is a mandatory component of Selenomethionine for oral and sublingual use.

Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.

When for oral use, the medicine requires the following warning statement on the medicine label:

- (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micograms for adults of selenium from dietary supplements should not be exceeded.’

 

4493

SELF-EMULSIFYING GLYCERYL MONOSTEARATE

E

 

4494

SEMECARPUS ANACARDIUM

A, H

When the plant part is other than seed, the maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material.

 

4495

SEMOLINA

E

 

4496

SEMPERVIVUM TECTORUM

A, H

 

4497

SENEGA ROOT DRY

A, H

 

4498

SENEGA ROOT POWDER

A, H

 

4499

SENNA ALEXANDRINA

A, H

When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna alexandrina.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4500

SENNA FRUIT ALEXANDRIAN DRY

A, H

When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna fruit alexandrian dry.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4501

SENNA FRUIT ALEXANDRIAN POWDER

A, H

When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna fruit alexandrian powder.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4502

SENNA FRUIT TINNEVELLY DRY

A, H

When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna fruit tinnevelly dry.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4503

SENNA FRUIT TINNEVELLY POWDER

A, H

When for oral or sublingual, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna fruit tinnevelly powder.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4504

SENNA LEAF DRY

A, H

When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna leaf dry.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]';

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4505

SENNA LEAF POWDER

A, H

When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna Leaf Powder.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4506

SENNA OCCIDENTALIS

A, H

Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna occidentalis when the route of administration is oral administration.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' [or words to that effect].

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' [or words to that effect].

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended;

- (LAX1) 'Drink plenty of water' [or words to that effect]; and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4507

SENNA TORA

A, H

When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna tora.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4508

SEPIA

H

Only for use as an active homoeopathic ingredient.

The requirement specified in paragraph (a) below applies to a medicine that contains the ingredient that is:

- listed in the Register on or after 1 March 2022; or

- released for supply on or after 1 March 2023.

(a) The following warning statement is required on the medicine label:

- (MOLLUSC) ‘Contains mollusc’ or ’Contains mollusc products’.

 

4509

SEQUOIA SEMPERVIRENS

A, H

 

4510

SEQUOIADENDRON GIGANTEUM

A, H

 

4511

SERENOA REPENS

A, H

 

4512

SERINE

A, E

 

4513

SERUM ANGUILLAE

H

Only for use as an active homoeopathic ingredient. 

 

4514

SESAME OIL

A, E, H

 

4515

SESAME SEED

E

 

4516

SESAMUM INDICUM

A, E, H

 

4517

SETARIA ITALICA

A, H

 

4518

SHARK CALCIUM CHONDROITIN SULFATE

A

 

4519

SHARK CARTILAGE

A, E

The medicine requires the following warning statement on the medicine label:

- (SHARK) 'Children, pregnant or breastfeeding women, and those who have recently had a heart attack, surgery or a major accident should not consume this product without medical advice' (or words to that effect)

 

4520

SHARK CHONDROITIN SULFATE

A, E

When used as an excipient:

- only for use in topical medicines for dermal application;

- not to be included in medicines intended for use in the eye; and

- the concentration in the medicine must be no more than 0.001%.

 

4521

SHARK POTASSIUM CHONDROITIN SULFATE

A

 

4522

SHARK SODIUM CHONDROITIN SULFATE

A, E

When used as an excipient:

- only for use in topical medicines for dermal application;

- not to be included in medicines intended for use in the eye; and

- the concentration in the medicine must be no more than 0.001%.

 

4523

SHARK-LIVER OIL

A, E

Vitamin A and Colecalciferol are mandatory components of Shark-liver oil.

When for internal use, the maximum recommended daily dose must be no more than 25 micrograms of Vitamin D.

When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.

When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.

When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:

- (VITA2) ‘WARNING: If you are pregnant - or considering becoming pregnant - do not take vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA4) ‘WARNING - When taken in excess of 3000 micrograms retinol equivalents - vitamin A can cause birth defects.’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA3) ‘The recommended daily amount of vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.’

 

4524

SHEA BUTTER

E

 

4525

SHEA BUTTER UNSAPONIFIABLES

E

Only for use in topical medicines for dermal application.

 

4526

SHELLAC

E

 

4527

SHEPHERD'S PURSE HERB DRY

A, H

 

4528

SHEPHERD'S PURSE HERB POWDER

A, H

 

4529

SHERRY WINE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4530

SIGESBECKIA ORIENTALIS

A, E, H

 

4531

SILICA

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4532

SILICA DIMETHYL SILYLATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4%.

 

4533

SILICA SILYLATE

E

Only for use in topical medicines for dermal application.

 

4534

SILICIFIED MICROCRYSTALLINE CELLULOSE

E

Only for use when the route of administration is other than inhalation.

 

4535

SILICON DIOXIDE

A, E, H

Only for use when the route of administration is other than inhalation.

 

4536

SILICONE QUATERNIUM-8

E

Only for use in wash-off topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2.5%.

The medicine requires the following warning statement on the medicine label:

- (EYE) 'Avoid contact with eyes' (or words to that effect).

 

4537

SILVER

H

Only for use as an active homoeopathic ingredient.

When for external use, the total concentration of silver in the medicine must not be more than 1%.

When for oral use:

(a) the total concentration of silver in the medicine must not be more than 0.3%; and

(b) the following warning statement is required on the medicine label:

- ‘Overuse may stain skin or mouth.’ (or words to that effect).

 

4538

SILVER BEET

E, H

 

4539

SILVER BOROSILICATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine should be no more than 0.6%.  

Silver is a mandatory component of Silver borosilicate when the route of administration is topical.

The concentration of silver in the medicine must be no more than 1%.

 

4540

SILVER NITRATE

H

Only for use as an active homoeopathic ingredient. 

 

4541

SILYBUM MARIANUM

A, E, H

 

4542

SIMABA CEDRON

A, H

 

4543

SIMETHICONE

E

 

4544

SIMMONDSIA CHINENSIS

A, E, H

 

4545

SINAPIS ALBA

A, H

Allyl isothiocyanate is a mandatory component of Sinapis alba when the plant part is seed.

The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.

 

4546

SINAPIS ARVENSIS

A, H

 

4547

SINOMENIUM ACUTUM

A, H

 

4548

SIPHONESTEGIA CHINENSIS

A, H

 

4549

SIRAITIA GROSVENORII

A, E, H

 

4550

SISYMBRIUM OFFICINALE

A, H

 

4551

SKATOLE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4552

SKIPJACK-LIVER OIL

A, E

Vitamin A and Colecalciferol are mandatory components of Skipjack-liver oil.

When for internal use, the maximum recommended daily dose must be no more than 25 micrograms of Vitamin D.

When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.

When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.

When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:

- (VITA2) ‘WARNING: If you are pregnant - or considering becoming pregnant - do not take vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA4) ‘WARNING - When taken in excess of 3000 micrograms retinol equivalents - vitamin A can cause birth defects.’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA3) ‘The recommended daily amount of vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.’

 

4553

SLIPPERY ELM BARK DRY

A, H

 

4554

SLIPPERY ELM BARK POWDER

A, E, H

 

4555

SMILAX ARISTOLOCHIIFOLIA

A, H

 

4556

SMILAX CHINA

A, H

 

4557

SMILAX GLABRA

A, H

 

4558

SMILAX OFFICINALIS

A, E, H

 

4559

SMILAX ORNATA

A, E, H

 

4560

SMOKE EXTRACT

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4561

SODIUM ACETATE

E

 

4562

SODIUM ACETYLATED HYALURONATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

4563

SODIUM ACID CITRATE

A, E, H

When sodium acid citrate is used as an active ingredient, only for use in oral medicines.

 

4564

SODIUM ACRYLATES COPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.8%.

 

4565

SODIUM ACRYLATES CROSSPOLYMER-2

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.7 % (w/w).

 

4566

SODIUM ACRYLOYDIMETHYLTAURATE/VP CROSSPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 2% (w/w).

 

4567

SODIUM ALGINATE

E

 

4568

SODIUM ASCORBATE

A, E, H

 

4569

SODIUM ASCORBYL PHOSPHATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

When used in a sunscreen, the concentration in the medicine must be no more than 0.1%.

 When used in products other than sunscreens, the concentration in the medicine must be no more than 0.5%.

 

4570

SODIUM ASCORBYL/CHOLESTERYL PHOSPHATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4571

SODIUM BENZOATE

E

 

4572

SODIUM BETA-HYDROXY-BETA-METHYLBUTYRATE

A, H

 

4573

SODIUM BETA-HYDROXY-BETA-METHYLBUTYRATE MONOHYDRATE

A, H

 

4574

SODIUM BICARBONATE

A, E

When used as an active ingredient, the medicine may only be for oral rehydration salts in powdered and effervescent tablet dosage forms.

Medicines containing sodium bicarbonate for use as oral rehydration therapy are subject to the following conditions:

a) the medicine complies with the requirements specified in the British Pharmacopoeia, as in force or existing from time to time, for Oral Rehydration Salts;

b) the sodium content and total osmolarity of the solution after it has been prepared according to the instructions on the packet are consistent with the criteria specified by the World Health Organisation (WHO) and the United Nations Childrens Fund (UNICEF) in the document 'Expert consultation on oral rehydration salts formulation 18 July 2001.'

c) the following warning statements are required on the medicine label:

- (UOAD) 'Use only as directed.'

- (DIAR) 'If diarrhoea persists for more than 6 hours in infants under 6 months - 12 hours in children under 3 years - 24 hours in children aged 3-6 years or 48 hours in adults and children over 6 years - seek medical advice (or words to that effect).'

- (DIAR3) 'If diarrhoea persists, seek medical advice.'

 

4575

SODIUM BISULFITE

E

 

4576

SODIUM BROMIDE

H

Only for use as an active homoeopathic ingredient.

The total concentration of sodium bromide in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.

 

4577

SODIUM BUTYRATE

A, E

The route of administration for medicines that contain sodium butyrate must be limited to oral.

The maximum recommended daily dose of the medicine must not provide more than 1200 mg sodium butyrate.

The following warning statement (or words to the same effect) is required on the medicine label:

- (ADULT) 'Adults only’.

 

4578

SODIUM C14-16 OLEFIN SULFONATE

E

Only for use in topical medicines for dermal application.

 

4579

SODIUM CALCIUM EDETATE

E

When for oral use, sodium is a mandatory component of sodium calcium edetate.

Sodium calcium edetate must only be included in medicines when:

(a) the route of administration is limited to topical for dermal use; or

(b) in combination with other permitted ingredients as a flavour proprietary excipient formulation.

The total concentration of sodium calcium edetate in the medicine must not exceed 0.32%.

The total concentration of flavour proprietary excipient formulations containing sodium calcium edetate must not be more than 5% of the total medicine.

 

4580

SODIUM CARBOMER

E

Only for use as an excipient in topical medicines for dermal application.

 

4581

SODIUM CARBONATE

E

 

4582

SODIUM CARBONATE MONOHYDRATE

E

 

4583

SODIUM CARBOXYMETHYL BETAGLUCAN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.005%.

 

4584

SODIUM CARRAGEENAN

E

 

4585

SODIUM CASEINATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4586

SODIUM CETOSTEARYL SULFATE

E

Only for use in topical medicines for dermal application.

 

4587

SODIUM CHLORIDE

A, E, H

 

4588

SODIUM CHONDROITIN SULFATE

A, E

When used as an excipient ingredient:

a) only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye;

b) the concentration in the medicine must not be more than 0.001%.

When used as an active ingredient:

a) the route of administration must only be oral;

b) the maximum daily dose must not provide more than 1,200 mg of sodium chondroitin sulfate;

c) the following statements must be included on the medicine label:

- (ADULT) ‘Adults only' (or words to that effect);

- (PREGNT) ‘Not recommended for use by pregnant and lactating women’ (or words to that effect).

 

4589

SODIUM CITRATE

A, E

When for use as an active ingredient, only for oral use.

 

4590

SODIUM CITRATE DIHYDRATE

A, E

When for use as an active ingredient, only for oral use.

 

4591

SODIUM COCO PG-DIMONIUM CHLORIDE PHOSPHATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.05%.

 

4592

SODIUM COCOAMPHOACETATE

E

Only for use in topical medicines for dermal application.

 

4593

SODIUM COCOYL SARCOSINATE

E

Only for use in topical medicines for dermal application.

 

4594

SODIUM CYCLAMATE

E

 

4595

SODIUM DEHYDROACETATE

E

Only for use in topical medicines for dermal application.

 

4596

SODIUM DNA

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. 

The concentration in the medicine must be no more than 0.1%.

 

4597

SODIUM DODECYLBENZENESULFONATE

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 30%.

 

4598

SODIUM ERYTHORBATE

E

 

4599

SODIUM ETHYL HYDROXYBENZOATE

E

 

4600

SODIUM FLUORIDE

A, E, H

Fluoride is a mandatory component of sodium fluoride.

The route of administration must be limited to dental.

The dosage form must be limited to pastes, powders and/or gels for dental hygiene.

When used as an active ingredient, the medicine is subject to the following conditions:

(a) only for use in combination with at least one other active ingredient; and

(b) the concentration of fluoride ion in the medicine must not be more than 1,500 mg/kg.

When the concentration of fluoride ion is more than 1000 mg/kg, the medicine requires the following statements on the medicine label:

- (DNTSW) 'Do not swallow.'

- (CHILD4) 'Do not use [this product/insert name of product] in children 6 years of age or less.'

 

4601

SODIUM FUMARATE

E

 

4602

SODIUM HYALURONATE

A, E

When for use as an excipient ingredient, sodium hyaluronate must only be used in medicines with a topical route of administration for dermal application.

When for use as an active ingredient:

(a) the molecular mass of sodium hyaluronate must be between 600 and 1600 kilodaltons; and

(b) sodium hyaluronate must only be used in medicines when the route of administration is limited to:

(i) topical for dermal application; or

(ii) oral.

When for use in a topical medicine for dermal application the concentration of sodium hyaluronate in the medicine must not exceed 2.0%.

When for use as an active ingredient and the route of administration is oral:

(a) the maximum recommended daily dose must not provide more than 200 milligrams sodium hyaluronate;

(b) the recommended duration of use of the medicine must be limited to three months; and

(c) the following warning statements (or words to the same effect) are required on the medicine label :

- (ADULT) 'Adults only’; and

- (PREGNT) ' Not recommended for use by pregnant and lactating women'.

 

4603

SODIUM HYDROGENATED TALLOW GLUTAMATE

E

Only for use in topical medicines for dermal application.

 

4604

SODIUM HYDROXIDE

E

The concentration of sodium hydroxide in the medicine must not be more than 5%.

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

 

4605

SODIUM HYDROXYCITRATE

A

 

4606

SODIUM HYDROXYETHYL ACRYLATE/ACRYLOYLDIMETHYL TAURATE COPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1.5%.

 

4607

SODIUM HYDROXYMETHYLGLYCINATE

E

Only for use in topical medicines for dermal application.

 

4608

SODIUM HYPOCHLORITE

E

Chlorine is a mandatory component of sodium hypochlorite.

The concentration of chlorine in the medicine must not be more than 4%.

 

4609

SODIUM ISOSTEAROYL LACTYLATE

E

Only for use in topical medicines for dermal application.

 

4610

SODIUM LACTATE

E

 

4611

SODIUM LAURETH SULFATE

E

 

4612

SODIUM LAUROAMPHOACETATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4613

SODIUM LAUROYL METHYL ISETHIONATE

E

Only for use in wash-off topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 11%.

 

4614

SODIUM LAUROYL SARCOSINATE

E

Only for use in topical medicines for dermal application.

 

4615

SODIUM LAURYL PHOSPHATE

E

 

4616

SODIUM LAURYL SULFATE

E

 

4617

SODIUM LAURYL SULFOACETATE

E

Only for use in topical medicines for dermal application.

 

4618

SODIUM MAGNESIUM SILICATE

E

Only for use in topical medicines for dermal application.

 

4619

SODIUM MANNOSE PHOSPHATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

4620

SODIUM METABISULFITE

E

 

4621

SODIUM METAPHOSPHATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or damaged skin.

The concentration in the medicine must not be more than 0.1%.

 

4622

SODIUM METHYL COCOYL TAURATE

E

Only for dental use.

The concentration in the medicine must be no more than 2%.

 

4623

SODIUM METHYL HYDROXYBENZOATE

E

 

4624

SODIUM MOLYBDATE DIHYDRATE

A

Only for use in oral medicines.

Molybdenum is a mandatory component of Sodium molybdate dihydrate.

The percentage of molybdenum from sodium molybdate dihydrate should be calculated based on the molecular weight of sodium molybdate dihydrate.

The maximum daily dose of molybdenum from Sodium molybdate dihydrate must be no more than 125 micrograms.

 

4625

SODIUM MONOFLUOROPHOSPHATE

A

Fluoride is a mandatory component of sodium monofluorophosphate.

The route of administration must be limited to dental.

The dosage form must be limited to pastes, powders and/or gels for dental hygiene.

When sodium monofluorophosphate is used as an active ingredient, it is subject to the following conditions:

(a) only for use in combination with at least one other active ingredient; and

(b) the concentration of fluoride ion in the medicine must not be more than 1,500 mg/kg.

When the concentration of fluoride ion is more than 1000 mg/kg, the following warning statements are required on the medicine label:

- (DNTSW) 'Do not swallow.'

- (CHILD4) 'Do not use [this product/insert name of product] in children 6 years of age or less.'

 

4626

SODIUM MYRISTOYL GLUTAMATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. 

The concentration in the medicine must be no more than 0.0164%.

 

4627

SODIUM NITRATE

H

Only for use as an active homoeopathic ingredient.

 

4628

SODIUM NONOXYNOL-4 SULFATE

E

Only for use in topical medicines for dermal application.

 

4629

SODIUM PANTOTHENATE

A, E, H

 

4630

SODIUM PCA

E

Only for use in topical medicines for dermal application.

 

4631

SODIUM PERBORATE

A, H

Boron is a mandatory component of sodium perborate.

When for internal use, the maximum recommended daily dose must not provide more than 6 mg of boron.

When used in preparations for dermal use, which are not for paediatric or antifungal use, the concentration of boron from all ingredients in the product must not exceed 3500 mg/kg or 3500 mg/L or 0.35%.

When the maximum recommended daily dose of the medicine provides more than 3 mg of boron and the medicine is for internal use and/or oral application, one of the following warning statements is required on the label:

- (NTAKEN12) 'Not to be taken by children under 12 years old' (or words to that effect); or

- (ADULT) 'Adults only' (or words to that effect).

When the maximum recommended daily dose of the medicine provides more than 1 mg boron and up to, and including, 3 mg of boron, and the medicine is for internal use and/or oral application, one of the following warning statements is required on the label:

- (NTAKEN2) 'Not to be taken by children under 2 years old' (or words to that effect); or

- (ADULT) 'Adults only' (or words to that effect).

When for excipient use and the maximum recommended daily dose of the medicine provides more than 1 mg of boron and the medicine is for internal use and/or oral application, the following warning statement is required on the label:

- (BORON) 'Contains boron' (or words to that effect).

When the medicine is for topical use for dermal application, the following warning statement is required on the label:

- (BROKEN) 'Use on unbroken skin only' (or words to that effect).

 

4632

SODIUM PERCARBONATE

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 15%.

 

4633

SODIUM POLYACRYLATE

E

Only for use in topical medicines for dermal application.

 

4634

SODIUM POLYACRYLATE STARCH

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 1%.

 

4635

SODIUM POLYMETAPHOSPHATE

E

 

4636

SODIUM PROPIONATE

E

 

4637

SODIUM PROPYL HYDROXYBENZOATE

E

 

4638

SODIUM RNA

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.2%.

 

4639

SODIUM SELENATE

A, H

Selenium is a mandatory component of sodium selenate.

Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.

When for oral use, the medicine requires the following warning statement on the medicine label:

- (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.'

 

4640

SODIUM SELENATE DECAHYDRATE

A

Selenium is a mandatory component of sodium selenate decahydrate.

Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.

When for oral use, the medicine requires the following warning statement on the medicine label:

- (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.'

 

4641

SODIUM SELENITE

A, H

Selenium is a mandatory component of Sodium selenite.

Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.

When for oral use, the medicine requires the following warning statement on the medicine label:

- (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.’

 

4642

SODIUM SELENITE PENTAHYDRATE

A

Selenium is a mandatory component of Sodium selenite pentahydrate.

Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.

When for oral use, the medicine requires the following warning statement on the medicine label:

- (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.’

 

4643

SODIUM SILICATE

E

 

4644

SODIUM STARCH GLYCOLLATE

E

 

4645

SODIUM STARCH GLYCOLLATE TYPE A

E

 

4646

SODIUM STEARATE

E

Only for use in topical medicines for dermal application.

 

4647

SODIUM STEAROXY PG-HYDROXYETHYLCELLULOSE SULFONATE

E

Only for use in topical medicines for dermal application and not to be used in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 2%.

 

4648

SODIUM STEAROYL GLUTAMATE

E

Only for use in topical medicines for dermal application and not to be used in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 2.5%.

 

4649

SODIUM STEAROYL LACTYLATE

E

Only for use in topical medicines for dermal application.

 

4650

SODIUM STEARYL PHTHALAMATE

E

Only for use in medicines for dermal application and not to be used in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 1.5%.

 

4651

SODIUM SUCCINATE

E

Only for use in topical medicines for dermal application.

 

4652

SODIUM SULFATE

A, E, H

When it is not intended to be a laxative, the following warning statement is required on the medicine label:

- (LAX4) 'Substance may have a laxative effect'.

 

4653

SODIUM SULFATE DECAHYDRATE

A, E, H

When it is not intended to be a laxative, the following warning statement is required on the medicine label:

- (LAX4) 'Substance may have a laxative effect'.

 

4654

SODIUM SULFITE

E

 

4655

SODIUM SULFITE HEPTAHYDRATE

E

Only for use in topical medicines for dermal application.

 

4656

SODIUM TRIPOLYPHOSPHATE

E

Only for use when the route of administration is topical for dermal application, mucous membrane (buccal mucosa) or dental.

Not to be included in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4657

SOLANUM DULCAMARA

A, H

When for internal use, steroidal alkaloids calculated as solanine is a mandatory component of Solanum dulcamara.

When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.

 

4658

SOLANUM FEROX

A, H

When for internal use, steroidal alkaloids calculated as solanine is a mandatory component of Solanum ferox.

When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.

 

4659

SOLANUM LYCOCARPUM FRUIT EXTRACT

E

Only for use in topical medicines for dermal use and not to be included in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.02%.

 

4660

SOLANUM MELONGENA

A, H

When for internal use, steroidal alkaloids calculated as solanine is a mandatory component of Solanum melongena.

When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.

 

4661

SOLANUM NIGRUM

A, H

When for internal use, steroidal alkaloids calculated as solanine is a mandatory component of Solanum nigrum.

When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.

 

4662

SOLANUM TUBEROSUM

A, H

When for internal use, steroidal alkaloids calculated as solanine is a mandatory component of Solanum tuberosum.

When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.

 

4663

SOLIDAGO GIGANTEA

A, H

 

4664

SOLIDAGO GIGANTEA MIS

A, E, H

 

4665

SOLIDAGO VIRGAUREA

A, E, H

 

4666

SOLUBLE MAIZE STARCH

E

 

4667

SOLUBLE POTATO STARCH

E

 

4668

SOLVENT GREEN 3

E

Permitted for use only as a colour for topical use.

 

4669

SOLVENT RED 1

E

Permitted for use only as a colour for topical use.

 

4670

SOLVENT VIOLET 13

E

Permitted for use only as a colour for topical use.

 

4671

SOLVENT YELLOW 172

E

Permitted for use only as a colour for topical use.

The concentration in the medicine must be no more than 0.3%.

 

4672

SOLVENT YELLOW 33

E

Permitted for use only as a colour for topical use.

 

4673

SOPHORA FLAVESCENS

A, E, H

 

4674

SOPHORA TONKINENSIS

A, H

 

4675

SORBIC ACID

E

 

4676

SORBITAN ISOSTEARATE

E

Only for use in topical medicines for dermal application.

 

4677

SORBITAN MONO-OLEATE

E

 

4678

SORBITAN MONOLAURATE

E

 

4679

SORBITAN MONOSTEARATE

E

 

4680

SORBITAN OLEATE

E

 

4681

SORBITAN OLIVATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 10%.

 

4682

SORBITAN PALMITATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 2%.

 

4683

SORBITAN SESQUIISOSTEARATE

E

Only for use in topical medicines for dermal application.

 

4684

SORBITAN SESQUIOLEATE

E

Only for use in topical medicines for dermal application.

 

4685

SORBITAN STEARATE

E

 

4686

SORBITAN TRISTEARATE

E

Only for use in topical medicines for dermal application.

 

4687

SORBITOL

A, E

When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.

 

4688

SORBITOL SOLUTION (70 PER CENT) (CRYSTALLISING)

A, E

Sorbitol is a mandatory component of sorbitol solution (70 per cent) (crystallising).

When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.

 

4689

SORBITOL SOLUTION (70 PER CENT) (NON-CRYSTALLISING)

A, E

Sorbitol is a mandatory component of sorbitol solution (70 per cent) (non-crystallising).

When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.

 

4690

SORBUS AUCUPARIA

A, H

 

4691

SORGHUM

E

 

4692

SORGHUM VULGARE

A, H

 

4693

SOY PHOSPHATIDYLSERINE-ENRICHED SOY LECITHIN LIQUID

A

Soy phosphatidylserine is a mandatory component of soy phosphatidylserine-enriched soy lecithin liquid.

The concentration of soy phosphatidylserine in the medicine must be no more than 15%.

 

4694

SOY PHOSPHATIDYLSERINE-ENRICHED SOY LECITHIN POWDER

A

Soy phosphatidylserine is a mandatory component of soy phosphatidylserine-enriched soy lecithin powder.

The concentration of soy phosphatidylserine in the medicine must be no more than 15%.

 

4695

SOY POLYSACCHARIDE

E

 

4696

SOY PROTEIN

E

 

4697

SOY STEROL

E

 

4698

SOYA BEAN

E

 

4699

SOYA BRAN

E

 

4700

SOYA OIL

A, E, H

 

4701

SOYBEAN FLOUR

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4702

SOYBEAN GLYCERIDES

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4%.

 

4703

SPARGANIUM STOLONIFERUM

A, H

 

4704

SPARTIUM JUNCEUM

A, H

 

4705

SPATHOLOBUS SUBERECTUS

A, H

 

4706

SPEARMINT OIL

A, E, H

Menthol is a mandatory component of spearmint oil.

When the medicine is for topical use for dermal application:

(i) the medicine must not be intended for use in the eye or on damaged skin;

(ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;

(iii) the following warning statement is required on the medicine label:

- (EYE) Avoid contact with eyes (or words to that effect).

(iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use.

(v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label:

– (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.

When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

4707

SPEARMINT OIL TERPENELESS

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Menthol is a mandatory component of spearmint oil terpeneless.

When the medicine is for topical use for dermal application:

i) the medicine must not be intended for use in the eye or on damaged skin;

ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;

iii) the following warning statement is required on the medicine label:

- (EYE) Avoid contact with eyes (or words to that effect).

iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use.

v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label:

– (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.

When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

4708

SPHINGOLIPIDS

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

4709

SPIGELIA ANTHELMIA

A, H

 

4710

SPIGELIA MARILANDICA

A, H

The maximum recommended daily dose must be no more than the equivalent of 1mg of the dry herbal material.

 

4711

SPIKE LAVENDER OIL

A, E, H

Camphor is a mandatory component of spike lavender oil.

In solid and semi solid preparations, the concentration of camphor must be no more than 12.5%.

In liquid preparations other than essential oils, the concentration of camphor must be no more than 2.5%.

In essential oil preparations, if the concentration of camphor is more than 2.5% but less than or equal to 10%, and the nominal capacity of the container is less than 25 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is less than 15 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, the medicine must have a restricted flow insert and child resistant closure fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

If the concentration of camphor is more than 2.5%, the nominal capacity of the container must be no more than 25 millilitres.

 

4712

SPINACH

E

 

4713

SPINACIA OLERACEA

A, E, H

 

4714

SPIRODELA POLYRRHIZA

A, H

 

4715

SPIRULINA

E

 

4716

SPRAY-DRIED GLUCOSE SYRUP

E

Permitted for use as an excipient for oral routes of administration.

 

4717

SPRAY-DRIED LIQUID GLUCOSE

E

Permitted for use as an excipient for oral routes of administration.

 

4718

SPRUCE OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4719

SQUALANE

E

Only for use in topical medicines for dermal application.

 

4720

SQUALENE

A, E

 

4721

SQUID OIL

A

Only for use in oral medicines.

Must be obtained from species of the order Teuthida of the class Cephalopoda, be used in combination with other ingredients in the medicine and be presented in a therapeutic dosage form for therapeutic use.

The requirement specified in paragraph (a) below applies to a medicine that contains the ingredient that is:

- listed in the Register before 1 March 2022; and

- released for supply before 1 March 2023.

(a) The medicine requires one of the following warning statements on the medicine label:

- (SFOOD) 'Derived from seafood'; or

- (MOLLUSC) ‘Contains mollusc’ or ’Contains mollusc products’.

The requirement specified in paragraph (b) below applies to a medicine that contains the ingredient that is:

- listed in the Register on or after 1 March 2022; or

- released for supply on or after 1 March 2023.

(b) The following warning statement is required on the medicine label:

- (MOLLUSC) ‘Contains mollusc’ or ’Contains mollusc products’.

 

4722

SQUILL DRY

A, H

 

4723

SQUILL INDIAN DRY

A, H

 

4724

SQUILL INDIAN POWDER

A, H

 

4725

SQUILL POWDER

A, H

 

4726

ST JOHN'S WORT DRY EXTRACT QUANTIFIED

A

When used for oral ingestion, the medicine requires the following warning statement on the medicine label:

- (STJOHN) 'St John's Wort affects the way many prescription medicines work - including oral contraceptives. Consult your doctor.'

 

4727

ST JOHN'S WORT HERB DRY

A, H

When used for oral ingestion, the medicine requires the following warning statement on the medicine label:

- (STJOHN) 'St John's Wort affects the way many prescription medicines work - including oral contraceptives. Consult your doctor.'

 

4728

ST JOHN'S WORT HERB POWDER

A, H

When used for oral ingestion, the medicine requires the following warning statement on the medicine label:

- (STJOHN) 'St John's Wort affects the way many prescription medicines work - including oral contraceptives. Consult your doctor.'

 

4729

STACHYS OFFICINALIS

A, E, H

 

4730

STACHYS PALUSTRIS

A, H

 

4731

STACHYURUS HIMALAICUS

A, H

 

4732

STANNIC OXIDE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.005%.

 

4733

STANNOUS CHLORIDE

H

Only for use as an active homoeopathic ingredient. 

 

4734

STAR ANISE OIL

A, E

When the total concentration of star anise oil in the medicine is more than 50%:

(a) the nominal capacity of the container must not be more than 50 mL;

(b) a restricted flow insert must be fitted on the container; and

(c) the following warning statement is required on the medicine label:

- (CHILD) ‘Keep out of reach of children’ (or words to that effect).

 

4735

STARCH

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4736

STARCH SODIUM OCTENYL SUCCINATE

E

 

4737

STEARALKONIUM CHLORIDE

E

Only for use in topical medicines for dermal application.

 

4738

STEARALKONIUM HECTORITE

E

Only for use in topical medicines for dermal application.

 

4739

STEARAMIDE

E

Only for use in topical medicines for dermal application.

 

4740

STEARAMIDOETHYL DIETHYLAMINE

E

Only for use in topical medicines for dermal application.

 

4741

STEARAMIDOPROPYL DIMETHYLAMINE

E

Only for use in topical medicines for dermal application.

 

4742

STEARAMIDOPROPYL PG-DIMONIUM CHLORIDE PHOSPHATE

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 2%.

When the medicine is intended to be used on the eye, the medicine requires the following warning statement on the medicine label:

- (EYE2) 'May be irritant to the eyes' (or words to that effect).

 

4743

STEARETH-10

E

Only for use in topical medicines for dermal application.

 

4744

STEARETH-100

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1.5%.

 

4745

STEARETH-2

E

Only for use in topical medicines for dermal application.

 

4746

STEARETH-20

E

Only for use in topical medicines for dermal application.

 

4747

STEARETH-21

E

Only for use in topical medicines for dermal application.

 

4748

STEARETH-5

E

Only for use in topical medicines for dermal application.

 

4749

STEARIC ACID

E

 

4750

STEAROPTENES

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4751

STEAROXY DIMETHICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4%.

 

4752

STEAROXYTRIMETHYLSILANE

E

Only for use in topical medicines for dermal application.

 

4753

STEAROYL MACROGOLGLYCERIDES

E

Only for use in oral medicines.

The concentration in the medicine must be no more than 0.6%.

 

4754

STEARYL ACETATE

E

Only for use in topical medicines for dermal application.

 

4755

STEARYL ALCOHOL

E

 

4756

STEARYL BEHENATE

E

Only for use as an excipient ingredient for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 3.5% in the final formulation.

 

4757

STEARYL DIMETHICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4.5%.

The medicine requires the following warning statements on the medicine label:

- (EYE2) 'May be irritant to the eyes' (or words to that effect)

- (EYE) 'Avoid contact with eyes' (or words to that effect).

 

4758

STEARYL GLYCYRRHETINATE

E

Only for use in topical medicines for dermal application.

 

4759

STEARYL HEPTANOATE

E

Only for use in topical medicines for dermal application.

 

4760

STEARYL MYRISTATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4761

STEARYL STEARATE

E

Only for use in topical medicines for dermal application.

 

4762

STELLARIA CHAMAEJASME

A, H

 

4763

STELLARIA DICHOTOMA

A, H

 

4764

STELLARIA MEDIA

A, E, H

 

4765

STEMONA JAPONICA

A, H

 

4766

STEMONA SESSILIFOLIA

A, H

 

4767

STENOTAPHRUM SECUNDATUM

A, H

 

4768

STEPHANIA TETRANDA

A, H

 

4769

STERCULIA

A, H

 

4770

STERCULIA TRAGACANTHA

A, H

 

4771

STERCULIA URENS

A, H

 

4772

STEVIA REBAUDIANA

A, E, H

 

4773

STEVIOL GLYCOSIDES

E

Only for use in oral medicines.

 

4774

STILLINGIA SYLVATICA

A, H

 

4775

STORAX PREPARED

A, E, H

 

4776

STRAWBERRY

E

 

4777

STRAWBERRY ESSENCE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4778

STREPTOCOCCUS SALIVARIUS

A

Only permitted for use in medicines:

- that are for oral routes of administration; and

- when the strain of Streptococcus salivarius is confirmed to be K12 or M18.

The name of the Streptococcus salivarius strain must be declared on the label.

The following warning statement is required on the medicine label:

- (CHILD5) 'Use in children under 3 years is not recommended'.

 

4779

STREPTOCOCCUS THERMOPHILUS

A

 

4780

STROBILANTHES CUSIA

A, H

 

4781

STRONG AMMONIA SOLUTION

E

Ammonia is a mandatory component of strong ammonia solution.

The concentration of ammonia in the medicine must be no more than 0.5%.

When for internal use, the concentration in the medicine must be no more than 0.25%.

 

4782

STRONTIUM CARBONATE

H

Only for use as an active homoeopathic ingredient. 

 

4783

STROPHANTHUS GRATUS

H

Only for use as an active homoeopathic ingredient.

 

4784

STROPHANTHUS HISPIDUS

H

Only for use as an active homoeopathic ingredient.

 

4785

STRYCHNOS IGNATII

H

Only for use as an active homoeopathic ingredient. 

Strychnine (of Strychnos spp.) is a mandatory component of Strychnos ignatii.

The concentration of Strychnine (of Strychnos spp.) must be no more than 1 milligram/Kg or 1 milligram/L or 0.1%.

 

4786

STRYCHNOS NUX-VOMICA

A, H

Strychnine (of Strychnos spp.) is a mandatory component of Strychnos nux-vomica.

The concentration of Strychnine (of Strychnos spp.) must be no more than 1 milligram/Kg or 1 milligram/L or 0.1%.

 

4787

STYPHNOLOBIUM JAPONICUM

A, E, H

 

4788

STYRALLYL PROPIONATE

E

Only for use in medicines in combination with other permitted ingredients as a fragrance proprietary excipient formulation.

The total fragrance proprietary excipient formulation in a medicine must not be more than 1%.

 

4789

STYRAX BENZOIN

A, E, H

 

4790

STYRAX OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4791

STYRAX PARALLELONEURUM

A, H

 

4792

STYRAX TONKINENSIS

A, H

 

4793

STYRENE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

The total concentration of styrene in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.

 

4794

STYRENE/ACRYLATES COPOLYMER

E

Only for use in topical medicines for dermal application.

 

4795

STYROLYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4796

SUBLIMED SULFUR

H

Only for use as an active homoeopathic ingredient. 

 

4797

SUCCINIC ACID

E

 

4798

SUCRALOSE

E

 

4799

SUCROSE

E

 

4800

SUCROSE ACETATE ISOBUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4801

SUCROSE ACETATE PALMITATE STEARATE

E

Only for use in topical medicines for dermal application and not intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.3%.

 

4802

SUCROSE COCOATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2%.

 

4803

SUCROSE DISTEARATE

E

Only for use in topical medicines for dermal application.

 

4804

SUCROSE LAURATE

E

When for oral or sublingual use, sucrose is a mandatory component of sucrose laurate.

 

4805

SUCROSE OCTAACETATE

E

When for oral or sublingual use, sucrose is a mandatory component of sucrose octaacetate.

 

4806

SUCROSE PALMITATE

E

Only for use in topical medicines for dermal application.

 

4807

SUCROSE POLYCOTTONSEEDATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

 The concentration in the medicine must be no more than 1%.

The medicine requires the following warning statements on the medicine label:

- (EYE) 'Avoid contact with the eyes' (or words to that effect)

- (EYE2) 'May be irritant to the eyes' (or words to that effect).

 

4808

SUCROSE STEARATE

E

For use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

When for topical use, the concentration in the medicine must be no more than 0.25%.

For oral use as a manufacturing aid only.

When for oral use, the concentration in the medicine must be no more than 0.2 mg per dosage unit.

 

4809

SUCROSE TRISTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 2%.

 

4810

SUDAN III

E

Permitted for use only as a colour for topical use.

 

4811

SUGAR CANE WAX ALCOHOLS

A, H

The maximum recommended daily dose must not provide more than 12mg.

The medicine requires the following warning statements on the medicine label:

- (PREGNT) 'Not recommended for use by pregnant and lactating women' (or words to that effect).

 

4812

SUGARCANE

E, H

When for oral or sublingual use, sucrose is a mandatory component of sugarcane.

 

4813

SULFATED CASTOR OIL

E

Only for use in topical medicines for dermal application.

 

4814

SULFATED LOW MOLECULAR WEIGHT FUCANS

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.025%.

 

4815

SULFUR DIOXIDE

E

 

4816

SULFUR IODIDE

H

Only for use as an active homoeopathic ingredient. 

 

4817

SULFURIC ACID

E, H

Only for use as an active homoeopathic ingredient or excipient ingredient. 

The concentration in the medicine must be no more than 0.5%.

 

4818

SULFURISED 1-METHYL-4-(1-METHYLETHENYL)-CYCLOHEXENE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4819

SULISOBENZONE

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 10%.

When used in primary sunscreen products, the following warning statements are required on the label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

4820

SULISOBENZONE SODIUM

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 10%.

When used in primary sunscreen products, the following warning statements are required on the label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

4821

SUNFLOWER OIL

A, E, H

 

4822

SUNFLOWER SEED

E, H

 

4823

SUNSET YELLOW FCF

E

Permitted for use only as a colour for either topical use or with an oral route of administration.

 

4824

SUNSET YELLOW FCF ALUMINIUM LAKE

E

Permitted for use only as a colour in medicines limited to topical and oral routes of administration.

 

4825

SUPEROXIDE DISMUTASE

E

Only for use in topical medicines for dermal application.

 

4826

SWEDE

E

 

4827

SWEET ORANGE OIL TERPENES AND TERPENOIDS

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4828

SWEET POTATO

E

 

4829

SWERTIA CHIRATA

A, H

 

4830

SWIETENIA MAHOGANI

A, H

 

4831

SYAGRUS ROMANZOFFIANA

A, E, H

 

4832

SYMPHYOTRICHUM NOVI-BELGII

A, H

 

4833

SYMPHYTUM OFFICINALE

H

When used orally as an active homoeopathic ingredient, the concentration must be a dilution of 12X or more.

When used in topical medicines for dermal application, the concentration in the preparation must be no more than 10mg/kg or 10mg/L or 0.001%.

 

4834

SYMPLOCARPUS FOETIDUS

A, H

 

4835

SYNTHETIC BEESWAX

E

Only for use in topical medicines for dermal applications.

 

4836

SYNTHETIC TERPENE RESIN

E

Only for use in topical, oral or oral application medicines.

When the route of administration is oral, the dosage form must be chewing gum.

 

4837

SYNTHETIC WAX

E

 

4838

SYRINGA RETICULATA

A, H

 

4839

SYRINGA VULGARIS

A, H

 

4840

SYZYGIUM AROMATICUM

A, E, H

When the plant preparation is oil or distillate and the concentration of this oil or distillate in the product is greater than 25%, the nominal capacity of the container must be no more than 25 millilitres and the medicine must include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

When the plant preparation is oil or distillate, the concentration of this oil or distillate in the medicine is greater than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, a child resistant closure and restricted flow insert must be fitted on the container.

When the plant preparation is oil or distillate, the concentration of oil or distillate in the product is greater than 25% and the nominal capacity of the container is less than 15 millilitres, a restricted flow insert must be fitted on the container.

When the plant preparation is oil or distillate and the preparation is for topical use in the mouth, the preparation may not contain more than 5 millilitres of the oil or distillate and the concentration of oil or distillate in the product must not be greater than 25%.

 

4841

SYZYGIUM CUMINI

A, H

 

4842

SYZYGIUM JAMBOS

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 0.0693%.

 

4843

TABEBUIA SERRATIFOLIA

A, E, H

 

4844

TAGETES ERECTA

A, E, H

When used as an excipient ingredient, only for use in combination with other permitted ingredients as a flavour proprietary excipient formulation. The total flavour proprietary excipient formulation in a medicine must not be more than 5%.

 

4845

TAGETES MINUTA

A, E, H

 

4846

TAGETES OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4847

TAIPAN SNAKE

H

Only for use as an active homoeopathic ingredient.

 

4848

TALLOW

E

Only for use in topical medicines for dermal application.

 

4849

TALLOW GLYCERIDES

E

 

4850

TAMARINDUS INDICA

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4851

TAMARIX APHYLLA

A, H

 

4852

TAMARIX CHINENSIS

A, H

 

4853

TAMARIX GALLICA

A, H

 

4854

TAMUS COMMUNIS

A, H

If the plant part is fruit or root, the maximum recommended daily dose must be no more than 1mg of the equivalent dry fruit or dry root of Tamus communis.

 

4855

TANACETUM CINERARIIFOLIUM

A, H

The concentration in the medicine must be no more than 10%.

 

4856

TANACETUM PARTHENIUM

A, E, H

 

4857

TANACETUM VULGARE

A, H

Oil (of Tanacetum vulgare) is a mandatory component of Tanacetum vulgare.

The concentration of oil (of Tanacetum vulgare) in the medicine must be no more than 0.8%.

 

4858

TANGERINE OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4859

TANGERINE OIL COLDPRESSED

A, E, H

When used internally, oxedrine is a mandatory component of tangerine oil coldpressed.

The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams.

 

4860

TANNIC ACID

E

 

4861

TAPIOCA STARCH

E

 

4862

TARAXACUM MONGOLICUM

A, E, H

 

4863

TARAXACUM OFFICINALE

A, E, H

 

4864

TARO

E

 

4865

TARRAGON OIL

A, E, H

 

4866

TARTARIC ACID

E

 

4867

TARTRAZINE

E

Only for use as a colour.

Only for use in medicines for topical and oral administration.

 

4868

TARTRAZINE ALUMINIUM LAKE

E

Only for use as a colour.

Only for use in medicines for topical and oral administration.

 

4869

TASMANNIA LANCEOLATA

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4870

TAURINE

A, E

 

4871

TEA-STEARATE

E

Only for use in topical medicines for dermal application.

 

4872

TERMINALIA ARJUNA

A

Only for use in oral medicines.

Only for use when the plant part is bark.

The maximum recommended daily dose must be no more than 6 grams of Terminalia arjuna dried bark or its extract equivalents.

The medicine requires the following warning statements on the medicine label:

- (PREGNT) 'Not recommended for use by pregnant and lactating women' (or words to that effect)

- (CHILD2) 'Not suitable for children'.

 

4873

TERMINALIA BELLIRICA

A

Only for use when the preparation is as an aqueous extract of the fruit pericarp.

 

4874

TERMINALIA CATAPPA

A, H

 

4875

TERMINALIA CHEBULA

A, H

 

4876

TERMINALIA FERDINANDIANA

A, E, H

Only for use when the plant part is fruit flesh, fruit flesh dry or the preparation is as an aqueous extract of the fruit flesh.

When used as an excipient, the ingredient is only for use in topical medicines for dermal application and not to be included in medicines intended for use on damaged skin or in the eye.

When used as an excipient, the concentration in the medicine must be no more than 0.3%.

 

4877

TERMINALIA SERICEA

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

Only for use when the plant part is root bark.

Only methanol/water (90:10; V/V) extract of Terminalia sericea bark of the root is approved.

The concentration in the medicine must be no more than 0.1%.

 

4878

TERPENE RESIN

E

Terpene resin must only be included in medicines when in combination with other permitted ingredients as a proprietary excipient formulation in medicines with a dermal route of administration for topical application.

 

4879

TERPINEN-4-OL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4880

TERPINEOL

E

 

4881

TERPINEOL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4882

TERPINOLENE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4883

TERPINYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4884

TERPINYL BUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used as a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4885

TERPINYL METHYL ETHER

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4886

TERT-BUTYL ALCOHOL

E

Only for use in topical medicines for dermal application.

 

4887

TERT-BUTYL HYDROQUINONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4888

TERT-BUTYL METHYL ETHER

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4889

TERT-BUTYLPYRAZINE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4890

TETRACLINIS ARTICULATA

A, E, H

 

4891

TETRADECYL AMINOBUTYROYLVALYLAMINOBUTYRIC UREA TRIFLUOROACETATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.002%.

 

4892

TETRADIUM RUTICARPUM

A, H

When for internal use, oxedrine is a mandatory component of Tetradium ruticarpum.

The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 mg.

 

4893

TETRAHEXYLDECYL ASCORBATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

4894

TETRAHYDRO LINALYLACETATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4895

TETRAHYDRO PARA-METHYLQUINOLINE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4896

TETRAHYDRO-6-(3-PENTENYL)-2H-PYRAN-2-ONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4897

TETRAHYDRODIFERULOYLMETHANE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

4898

TETRAHYDROFURFURYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4899

TETRAHYDROGERANYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4900

TETRAHYDROLINALOOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4901

TETRAHYDROMUGUOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4902

TETRAHYDROMYRCENOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4903

TETRAHYDROXYPROPYL ETHYLENEDIAMINE

E

Only for use in topical medicines for dermal application.

 

4904

TETRAMETHYL ACETYLOCTAHYDRONAPHTHALENES

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4905

TETRAPANAX PAPYRIFER

A, H

 

4906

TETRASODIUM ETIDRONATE

E

Only for use in topical medicines for dermal application.

 

4907

TETRASODIUM PYROPHOSPHATE

E

 

4908

TEUCRIUM CHAMAEDRYS

A, H

The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material of Teucrium chamaedrys.

 

4909

TEUCRIUM MARUM

A, H

The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material of Teucrium marum.

 

4910

TEUCRIUM SCORODONIA

A, H

The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material of Teucrium scorodonia.

 

4911

THAPSIA GARGANICA

A, H

 

4912

THAUMATIN

E

 

4913

THEASPIRANE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4914

THEMEDA TRIANDRA

A, H

 

4915

THEOBROMA CACAO

A, E, H

Caffeine is a mandatory component of Theobroma cacao.

When the medicine is packaged for supply as a divided preparation and is for internal use or oral application, the medicine must not contain a concentration of total caffeine greater than 33%.

When for internal use or oral application, the maximum recommended daily dose of the medicine must provide no more than 400 mg of total caffeine.

When the medicine is packaged for supply as an undivided preparation and is for internal use or oral application, the medicine must not contain a concentration of total caffeine greater than 1%.

When the medicine is for internal use or oral application, a maximum recommended dose of the medicine must not provide more than 100 mg of total caffeine within a 3 hour period.

When the maximum recommended daily dose of the medicine provides greater than 10 mg of total caffeine and the medicine is for internal use or oral application, the following warning statements are required on the label:

- (ADULT) 'Adults only' (or words to that effect).

- (CAFF) 'Contains [state quantity per dosage unit or per mL or per gram of product] total caffeine [per dosage unit or per mL or per gram]. A cup of instant coffee contains approximately 80 mg of caffeine.'

- (CAFFPREG) ‘Caffeine intake more than 200 mg per day is not recommended during pregnancy or breastfeeding.’

When the maximum recommended daily dose of the medicine provides greater than 80 mg of total caffeine and the medicines is for internal use or oral application, the following warning statements are required on the label:

- (CAFFLMT) 'Limit the use of caffeine-containing products (including tea and coffee) when taking this product.'

- (CAFFCYP) ‘Caffeine interacts with enzyme CYP1A2 in the liver. Consult your health professional before taking with other medicines’ (or words to that effect).

 

4916

THEOBROMA OIL

A, E, H

 

4917

THIAMINE

A, E

 

4918

THIAMINE HYDROCHLORIDE

A, E

 

4919

THIAMINE NITRATE

A, E

 

4920

THIOCINEOLE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4921

THIOTAURINE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.02%.

 

4922

THLASPI ARVENSE

A, E, H

 

4923

THREONINE

A, E

 

4924

THUJA OCCIDENTALIS

A, H

 

4925

THUJA PLICATA

A, E, H

 

4926

THYME HERB DRY

A, E, H

 

4927

THYME OIL

A, E, H

When the concentration of Thyme oil in the medicine is more than 50%, the nominal capacity of the container must be no more than 25 mL, a restricted flow insert must be fitted on the container and the medicine requires the warning statement:

- (CHILD) 'Keep out of reach of children' (or words to that effect).

 

4928

THYMOL

A, E

When used as an active ingredient, the medicine must be medicated space spray or medicated throat lozenges.

When used as an excipient, only for use in medicated throat lozenges or topical medicines for dermal applications.

 

4929

THYMOL METHYL ETHER

E

Thymol methyl ether must only be included in medicines when in combination with other permitted ingredients as a flavour proprietary excipient formulation.

The total concentration of the flavour proprietary excipient formulation containing thymol methyl ether must not be more than 5% of the total medicine.

 

4930

THYMUS CAPITATUS

A, E, H

When the plant preparation is an oil, and the concentration in the medicine is more than 50%, the nominal capacity of the container must be no more than 25 mL, a restricted flow insert must be fitted on the container and the medicine requires the following warning statement on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect).

 

4931

THYMUS GLAND

H

Only for use as an active homoeopathic ingredient. 

 

4932

THYMUS MASTICHINA

A, E, H

When the plant preparation is an oil, and the concentration in the medicine is more than 50%, the nominal capacity of the container must be no more than 25 mL, a restricted flow insert must be fitted on the container and the medicine requires the following warning statement on the medicine label:- (CHILD) 'Keep out of reach of children' (or words to that effect).

 

4933

THYMUS SERPYLLUM

A, E, H

When the plant preparation is an oil, and the concentration in the medicine is more than 50%, the nominal capacity of the container must be no more than 25 mL, a restricted flow insert must be fitted on the container and the medicine requires the following warning statement on the medicine label:- (CHILD) 'Keep out of reach of children' (or words to that effect).

 

4934

THYMUS VULGARIS

A, E, H

When the plant preparation is oil or distillate, and the concentration of Thymus vulgaris oil or distillate in the preparation is greater than 50%:

(a) the nominal capacity of the container must not be more than 25 millilitres;

(b) a restricted flow insert must be fitted on the container; and

(c) the following warning statement is required on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect).

 

4935

THYMUS VULGARIS MIS

A, E, H

When the plant preparation is an oil or distillate, and the concentration of Thymus vulgaris MIS oil or distillate in the preparation is greater than 50%:

(a) the nominal capacity of the container must not be more than 25 millilitres;

(b) a restricted flow insert must be fitted on the container; and

(c) the following warning statement is required on the label:

- (CHILD) 'Keep out of reach of children' (or words to that effect).

 

4936

THYMUS ZYGIS

A, H

When the plant preparation is an oil or a distillate, and the concentration of Thymus zygis oil or distillate in the preparation is greater than 50%:

(a) the nominal capacity of the container must not be more than 25 millilitres;

(b) a restricted flow insert must be fitted on the container; and

(c) the following warning statement is required on the label:

- (CHILD) 'Keep out of reach of children' (or words to that effect).

 

4937

TIGER SNAKE

H

Only for use as an active homoeopathic ingredient.

 

4938

TILACTASE

A

Must be derived from Aspergillus oryzae and comply with the relevant USP monograph.

 

4939

TILIA CORDATA

A, E, H

 

4940

TILIA PLATYPHYLLOS

A, E, H

 

4941

TILIA TOMENTOSA

A, H

 

4942

TILIA X VULGARIS

A, E, H

 

4943

TILIANTOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4944

TIN

H

Only for use as an active homoeopathic ingredient. 

 

4945

TINOSPORA CORDIFOLIA

A, H

 

4946

TINOSPORA SINENSIS

A, H

 

4947

TITANIUM DIOXIDE

A, E

For use as an active ingredient only in sunscreens for dermal application.

The concentration in sunscreens must be no more than 25%.

For use as an excipient only as a colour and only in medicines limited to oral and topical routes of administration.

Not to be included in medicines intended for use in the eye.

When used in primary sunscreen products, the following warning statements are required on the label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

4948

TOCOCYSTEAMIDE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.01%.

 

4949

TOCOFERSOLAN

E

Only for oral and topical use.

When for oral use, the concentration in the medicine must be no more than 10% w/w.

When used in topical medicines for dermal application, it is not to be included in medicines intended for use in the eye.

When for topical use, the concentration in the medicine must be no more than 0.1%

 

4950

TOCOPHEROL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4951

TOCOPHERYL GLUCOSIDE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use on damaged skin or in the eye.

The concentration in the medicine must be no more than 0.05%

 

4952

TOCOPHERYL LINOLEATE

E

Only for use in topical medicines for dermal application.

 

4953

TOCOPHERYL NICOTINATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration must not exceed 0.3%.

 

4954

TOLU BALSAM

A, E, H

 

4955

TOLUENE

E

The residual solvent limit for toluene is 8.9 mg per maximum recommended daily dose.

The concentration in the medicine must be no more than 0.089%.

 

4956

TOLYL ALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4957

TOLYLALDEHYDE GLYCERYLACETAL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4958

TOMATO

E

 

4959

TONKA

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4960

TONKA BEAN EXTRACT

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4961

TONONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4962

TOXICODENDRON DIVERSILOBUM

H

Only for use as an active homoeopathic ingredient. 

 

4963

TOXICODENDRON PUBESCENS

H

Only for use as an active homoeopathic ingredient.

The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material of Toxicodendron pubescens.

 

4964

TOXICODENDRON RADICANS

A, H

The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material of Toxicodendron radicans.

 

4965

TOXICODENDRON SUCCEDANEUM

H

Only for use as an active homoeopathic ingredient. 

 

4966

TRACHELOSPERMUM JASMINOIDES

A, E, H

 

4967

TRACHYSPERMUM AMMI

A, E

Only for use in oral medicines when the plant part is fruit or seed.

The medicine requires the following warning statements on the medicine label:

- (PREGNT) 'Not recommended for use by pregnant and lactating women' (or words to that effect)

- (PREGNT2) 'Do not use if pregnant or likely to become pregnant' (or words to that effect).

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4968

TRAGACANTH

A, E

 

4969

TRAMETES VERSICOLOR

A, H

 

4970

TRAMETES VERSICOLOR PROTEOGLYCAN CONCENTRATE

A, H

Only for use in oral medicines.

 

4971

TRANS,TRANS-2,4-DECADIEN-1-AL

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4972

TRANS,TRANS-2,4-HEXADIENAL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in the medicine must be no more than 1%.

The maximum daily dose must provide no more than 13.5 mg of Trans,Trans-2,4-Hexadienal.

 

4973

TRANS-1-(2,4,4-TRIMETHYL-2-CYCLOHEXEN-1-YL)-2-BUTEN-1-ONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4974

TRANS-2-DECENAL

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4975

TRANS-2-DODECENAL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4976

TRANS-2-HEPTEN-1-AL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4977

TRANS-2-HEXENAL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4978

TRANS-2-HEXENOIC ACID

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4979

TRANS-2-HEXENOL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4980

TRANS-2-HEXENYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4981

TRANS-2-HEXENYL PHENYLACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4982

TRANS-2-HYDROXYCINNAMIC ACID

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4983

TRANS-2-OCTENAL

E

trans-2-Octenal must only be included in medicines when in combination with other permitted ingredients as a fragrance proprietary excipient formulation.

The total concentration of the fragrance proprietary excipient formulation containing trans-2-octenal must not be more than 1% of the total medicine.

 

4984

TRANS-2-UNDECENAL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4985

TRANS-3-HEXENOIC ACID

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4986

TRANS-4-DECENAL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4987

TRANS-8-(1-METHYLETHYL)-1-OXASPIRO(4.5)DECAN-2-ONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4988

TRANS-ETHYL 2-OCTENOATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4989

TRANS-METHYL-2-HEXENOATE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4990

TREACLE

E

When for oral or sublingual use, sucrose is a mandatory component of treacle.

 

4991

TREEMOSS ABSOLUTE

E

Permitted for use only in combination with other permitted ingredients as part of a fragrance proprietary excipient formulation.

When included in a medicine for use on the lips the concentration of treemoss absolute must be no more than 0.02%.

When for dermal use or use on the hair the concentration of treemoss absolute must be no more than 0.1%

The total fragrance proprietary excipient formulation in a medicine must be no more than 1%.

 

4992

TREFRIW WELLS MINERAL WATER

A

When for internal use, iron is a mandatory component of Trefriw Wells mineral water.

Solid dosage forms containing more than 5 milligrams of elemental iron in each dosage unit are required to have a child resistant closure.

Liquid Preparations containing more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure.

Only able to be used when presented in single use sachets for therapeutic use as an iron supplement.

 

4993

TREHALOSE DIHYDRATE

E

When for oral use and the quantity of trehalose dihydrate per maximum recommended daily dose exceeds 20 grams, the quantity of trehalose dihydrate must be declared on the label.

 

4994

TREMELLA FUCIFORMIS

A, H

 

4995

TRIACETIN

E

 

4996

TRIACONTANYL PVP

E

Only for use in topical medicines for dermal application.

 

4997

TRIADICA SEBIFERA

A, H

 

4998

TRIBASIC POTASSIUM PHOSPHATE

A, E, H

When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of tribasic potassium phosphate.

When used in a solid medicine containing this ingredient, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid medicine containing this ingredient, the pH of the medicine must be no more than 11.5.

 

4999

TRIBASIC SODIUM PHOSPHATE

E

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

 

5000

TRIBEHENIN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 6%.

 

5001

TRIBEHENIN PEG-20 ESTERS

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 6%.

 

5002

TRIBULUS TERRESTRIS

A, E, H

 

5003

TRIBUTYL ACETYLCITRATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

5004

TRICALCIUM PHOSPHATE

E

 

5005

TRICAPRYLIN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

5006

TRICAPRYLYL CITRATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 7%.

 

5007

TRICETEARETH-4 PHOSPHATE

E

Only for use in topical medicines for dermal application.

 

5008

TRICHLOROMETHYLPHENYLCARBINYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

5009

TRICHODERMA VIRIDE

A, E, H

 

5010

TRICHOSANTHES KIRILOWII

A, E, H

 

5011

TRICLOSAN

E

The concentration in the medicine must be no more than 1%.

 

5012

TRICYCLODECENYL PROPIONATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

5013

TRIDECANAL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

5014

TRIDECETH-4 PHOSPHATE

E

Only for use in topical medicines for dermal application.

 

5015

TRIDECETH-6

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.5%.

 

5016

TRIDECYL ALCOHOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used as in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

5017

TRIDECYL BEHENATE

E

Behenic acid is a mandatory component of Tridecyl behenate.

Only for use in topical medicines for dermal application.

 

5018

TRIDECYL NEOPENTANOATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 23%.

 

5019

TRIDECYL SALICYLATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. 

The concentration in the medicine must be no more than 5%.

 

5020

TRIDECYL STEARATE

E

Only for use in topical medicines for dermal application.

 

5021

TRIDECYL TRIMELLITATE

E

Only for use in topical medicines for dermal application.

 

5022

TRIETHOXYCAPRYLYLSILANE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 1%.

 

5023

TRIETHYL CITRATE

E

 

5024

TRIETHYLENE GLYCOL

E

 

5025

TRIFOLIUM PRATENSE

A, E, H

 

5026

TRIFOLIUM REPENS

A, H

 

5027

TRIGONELLA FOENUM-GRAECUM

A, E, H

 

5028

TRIHYDROXYPALMITAMIDOHYDROXYPROPYL MYRISTYL ETHER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.02%.

 

5029

TRIHYDROXYSTEARIN

E

Only for use in topical medicines for dermal application.

 

5030

TRIISOCETYL CITRATE

E

Only for use in topical medicines for dermal application.

 

5031

TRIISODECYL TRIMELLITATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

5032

TRIISONONANOIN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

5033

TRIISOSTEARIN

E

Only for use in topical medicines for dermal application.

 

5034

TRILAURIN

E

Only for use in topical medicines for dermal application.

 

5035

TRILISA ODORATISSIMA

A, H

 

5036

TRILLIUM ERECTUM

A, H

 

5037

TRIMETHOXYCAPRYLYL SILANE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.25%.

 

5038

TRIMETHYL HYDROXYPENTYL ISOBUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

5039

TRIMETHYL UNDECYLENIC ALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

5040

TRIMETHYL-BICYCLO-HEPTANE-SPIROCYCLOHEXENONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

5041

TRIMETHYLBENZENEPROPANOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

5042

TRIMETHYLHEXANOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

5043

TRIMETHYLOPROPANE TRIOCTANOATE

E

Only for use in topical medicines for dermal application.

 

5044

TRIMETHYLPENTANEDIOL/ADIPIC ACID/GLYCERIN CROSSPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

5045

TRIMETHYLSILOXYSILICATE

E

Only for use in topical medicines for dermal application.

 

5046

TRINITROPHENOL

H

Only for use as an active homoeopathic ingredient.

The total concentration of trinitrophenol in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.

 

5047

TRIOCTANOIN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

5048

TRIOCTYLDODECYL CITRATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 12%.

 

5049

TRIOLEIN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

5050

TRIOSTEUM PERFOLIATUM

A, H

 

5051

TRIOXAUNDECANEDIOIC ACID

E

 

5052

TRIPAL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

5053

TRIPEPTIDE-1

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.002%.

 

5054

TRIS-BIPHENYL TRIAZINE

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 10%.

When used topically, the dosage form must not be spray.

When used in primary sunscreen products, the following warning statements are required on the label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

5055

TRISILOXANE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 40%.

 

5056

TRISODIUM EDETATE

E

Only for use in topical medicines for dermal application.

 

5057

TRISODIUM ETHYLENEDIAMINE DISUCCINATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.2%.

 

5058

TRISODIUM NTA

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.005%.

 

5059

TRISTEARIN

E

 

5060

TRITICUM AESTIVUM

A, E, H

Gluten is a mandatory component when the plant part is seed and the route of administration is other than topical and mucosal.

 

5061

TRITICUM DURUM

A, E, H

Gluten is a mandatory component when the plant part is seed and the route of administration is other than topical and mucosal.

 

5062

TRIUNDECANOIN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 11.2%.

 

5063

TROLAMINE

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 5%.

 

5064

TROLAMINE LAURIL SULFATE

E

Only for use in topical medicines for dermal application.

 

5065

TROLAMINE SALICYLATE

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 12%.

When used in primary sunscreen products, the following warning statements are required on the label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

5066

TROLLIUS CHINENSIS

A, H

 

5067

TROMETAMOL

E

 

5068

TROMETAMOL HYDROCHLORIDE

E

 

5069

TROPAEOLUM MAJUS

A, E, H

 

5070

TROPICAL RATTLESNAKE

H

Only for use as an active homoeopathic ingredient.

 

5071

TROPOLONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.01%.

 

5072

TSUGA CANADENSIS

A, H

 

5073

TULIPA EDULIS

A, H

Colchicine is a mandatory component of Tulipa edulis.

The concentration of colchicine in the medicine must be no more than 10 mg/kg or 10 mg/L or 0.001%.

 

5074

TURMERIC

E

Permitted for use only in combination with other permitted ingredients as a colour.

 

5075

TURNERA DIFFUSA

A, E, H

Beta-arbutin is a mandatory component of Turnera diffusa.

When for oral use, the maximum recommended daily dose must not provide more than 500 mg of beta-arbutin.

When for dermal application exclusively to the face:

a) the concentration of beta-arbutin in the medicine must not be more than 7%;

b) hydroquinone is a mandatory component; and

c) the concentration of hydroquinone must not be more than 10 mg/kg or 10 mg/L or 0.001%.

When for use other than oral or dermal application exclusively to the face, the concentration of beta-arbutin in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.

 

5076

TURNIP

E

 

5077

TURPENTINE OIL

A, E

The concentration in the medicine must be no more than 25%.

 

5078

TYPHA ANGUSTIFOLIA

A, H

 

5079

TYPHA LATIFOLIA

A, H

 

5080

TYPHONIUM GIGANTEUM

A, H

 

5081

TYROSINE

A, E